{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:51:30Z","timestamp":1791276690983,"version":"4.1.0"},"reference-count":564,"publisher":"American Association for the Advancement of Science (AAAS)","funder":[{"name":"Research Projects of Hubei Cancer Hospital","award":["2022SWZX01"],"award-info":[{"award-number":["2022SWZX01"]}],"id":[{"id":"https:\/\/ror.org\/05p38yh32","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Projects of Hubei Cancer Hospital","award":["2024HBCHYN07"],"award-info":[{"award-number":["2024HBCHYN07"]}],"id":[{"id":"https:\/\/ror.org\/05p38yh32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Over the past 5 decades, small cell lung cancer (SCLC) has persisted as one of the most formidable malignancies, largely attributed to its aggressive early metastasis, limited therapeutic arsenal in both first-line and subsequent treatments, and rapid onset of treatment resistance. The dawn of a new era in the treatment of SCLC appeared in 2018, with the introduction of first-line chemotherapy combined with immune checkpoint inhibitors, as well as tarlatamab for later-line treatment. However, the improvements in survival, although tangible, were still unsatisfactory. Therefore, this review focuses on unraveling the mechanisms underlying cancer initiation, progression, and particularly metastasis, as well as emerging advances in molecular subtyping and drug resistance from the epigenetic perspective. Simultaneously, we outline their hallmark characteristics\u2014high plasticity, heterogeneity, redundancy, and ambiguity driven by intercellular crosstalk under spatiotemporal dependency. Furthermore, we highlight the evolving progress of various successful drugs or therapeutic strategies and molecular biomarkers in clinical practice for SCLC, as well as promising agents under investigation. Finally, we also discuss how to leverage artificial intelligence and innovative biomedical technologies, as well as learn from various challenges in order to improve the therapeutic landscape of SCLC.<\/jats:p>","DOI":"10.34133\/cancomm.0052","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:38:36Z","timestamp":1787715516000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The Five-Decade Journey of Small Cell Lung Cancer"],"prefix":"10.34133","volume":"46","author":[{"given":"Runzhi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Xiangyang Central Hospital, \rAffiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tongji Medical College, Hubei Cancer Hospital, \rHuazhong University of Science and Technology, Wuhan, Hubei, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"1","key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin CM","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785"},{"issue":"1","key":"e_1_3_3_4_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00914-x"},{"issue":"2","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt X","year":"2025","unstructured":"Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nat Med. 2025;31(2):457\u2013465.","journal-title":"Nat Med"},{"key":"e_1_3_3_7_2","unstructured":"Key Statistics for Lung Cancer. 2025. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html"},{"issue":"1","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang Q","year":"2022","unstructured":"Wang Q, G\u00fcm\u00fc\u015f ZH, Colarossi C, Memeo L, Wang X, Kong CY, Boffetta P. SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2022;18(1):31\u201346.","journal-title":"J Thorac Oncol"},{"issue":"14","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.35281","article-title":"The changing landscape of small cell lung cancer","volume":"130","author":"Cittolin-Santos GF","year":"2024","unstructured":"Cittolin-Santos GF, Knapp B, Ganesh B, Gao F, Waqar S, Stinchcombe TE, Govindan R, Morgensztern D. The changing landscape of small cell lung cancer. Cancer. 2024;130(14):2453\u20132461.","journal-title":"Cancer"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112985","article-title":"Trends in the epidemiology of small-cell lung cancer: A Dutch nationwide population-based study over 1989-2020","volume":"191","author":"Dumoulin DW","year":"2023","unstructured":"Dumoulin DW, Aarts MJ, De Ruysscher D, Aerts JGJV, Dingemans A-MC. Trends in the epidemiology of small-cell lung cancer: A Dutch nationwide population-based study over 1989-2020. Eur J Cancer. 2023;191: Article 112985.","journal-title":"Eur J Cancer"},{"issue":"8","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/1759-7714.13412","article-title":"Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008-2017)","volume":"11","author":"Li D","year":"2020","unstructured":"Li D, Xu X, Liu J, Liang D, Shi J, Li S, Jin J, He Y. Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008-2017). Thorac Cancer. 2020;11(8):2087\u20132093.","journal-title":"Thorac Cancer"},{"issue":"24","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu Y","year":"2024","unstructured":"Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, Wang J, Zuo T, Li T, Zheng Y, et al. Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J. 2024;137(24):3093\u20133100.","journal-title":"Chin Med J"},{"key":"e_1_3_3_13_2","unstructured":"Cancer Incidence in Five Continents. 2023. https:\/\/ci5.iarc.who.int\/previous\/"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0620"},{"issue":"1","key":"e_1_3_3_15_2","article-title":"Racial and other healthcare disparities in patients with extensive-stage SCLC","volume":"2","author":"Tapan U","year":"2020","unstructured":"Tapan U, Furtado VF, Qureshi MM, Everett P, Suzuki K, Mak KS. Racial and other healthcare disparities in patients with extensive-stage SCLC. JTO Clin Res Rep. 2020;2(1): Article 100109.","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.101124","article-title":"Ethnic disparities in lung cancer incidence and differences in diagnostic characteristics: A population-based cohort study in England","volume":"48","author":"Tzu-Hsuan Chen D","year":"2024","unstructured":"Tzu-Hsuan Chen D, Hirst J, Coupland CAC, Liao W, Baldwin DR, Hippisley-Cox J. Ethnic disparities in lung cancer incidence and differences in diagnostic characteristics: A population-based cohort study in England. Lancet Reg Health Eur. 2024;48: Article 101124.","journal-title":"Lancet Reg Health Eur"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"issue":"578","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7488","article-title":"Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies","volume":"13","author":"Tlemsani C","year":"2021","unstructured":"Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye G-A, Schmidt KT, Desai P, Kim C, et al. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578): Article eabc7488.","journal-title":"Sci Transl Med"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-0375"},{"issue":"8","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41591-025-03810-8","article-title":"AI-powered fragmentomics of cell-free DNA for early detection of multiple cancers","volume":"31","year":"2025","unstructured":"AI-powered fragmentomics of cell-free DNA for early detection of multiple cancers. Nat Med. 2025;31(8):2504\u20132505.","journal-title":"Nat Med"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09503-z"},{"issue":"6","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccr.2011.04.019","article-title":"Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung","volume":"19","author":"Sutherland KD","year":"2011","unstructured":"Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19(6):754\u2013764.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314815.118"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1863"},{"issue":"6","key":"e_1_3_3_26_2","first-page":"505","article-title":"A new floating cell line derived from human pulmonary carcinoma of oat cell type","volume":"62","author":"Oboshi S","year":"1971","unstructured":"Oboshi S, Tsugawa S, Seido T, Shimosato Y, Koide T. A new floating cell line derived from human pulmonary carcinoma of oat cell type. GANN Jpn J Cancer Res. 1971;62(6):505\u2013514.","journal-title":"GANN Jpn J Cancer Res"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.097"},{"issue":"1","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nm.4239","article-title":"Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer","volume":"23","author":"Carter L","year":"2016","unstructured":"Carter L, Rothwell DG, Mesquita B, Smowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2016;23(1):114\u2013119.","journal-title":"Nat Med"},{"issue":"3","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","article-title":"Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model","volume":"4","author":"Meuwissen R","year":"2003","unstructured":"Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4(3):181\u2013189.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821745116"},{"issue":"10","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1158\/0008-5472.CAN-09-4228","article-title":"Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma","volume":"70","author":"Schaffer BE","year":"2010","unstructured":"Schaffer BE, Park K-S, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010;70(10):3877\u20133883.","journal-title":"Cancer Res"},{"issue":"11","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-0385","article-title":"Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition","volume":"8","author":"Jia D","year":"2018","unstructured":"Jia D, Augert A, Kim D-W, Eastwood E, Wu N, Ibrahim AH, Kim K-B, Dunn CT, Pillai SPS, Gazdar AF, et al. Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition. Cancer Discov. 2018;8(11):1422\u20131437.","journal-title":"Cancer Discov"},{"issue":"1","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.111990","article-title":"A multiplexed in\u00a0vivo approach to identify driver genes in small cell lung cancer","volume":"42","author":"Lee MC","year":"2023","unstructured":"Lee MC, Cai H, Murray CW, Li C, Shue YT, Andrejka L, He AL, Holzem AME, Drainas AP, Ko JH, et al. A multiplexed in\u00a0vivo approach to identify driver genes in small cell lung cancer. Cell Rep. 2023;42(1): Article 111990.","journal-title":"Cell Rep"},{"issue":"1","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41392-025-02378-6","article-title":"Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers","volume":"10","author":"Wang G-Z","year":"2025","unstructured":"Wang G-Z, Wang Z, Bai S-H, Tan Y, Zhong W-Z, Sun G-G, Liu Y-T, Pan B, Huang C, Wang D, et al. Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers. Signal Transduct Target Ther. 2025;10(1):290.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01143-2"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0441"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.12.005"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0796"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0656"},{"issue":"12","key":"e_1_3_3_40_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105603","article-title":"DLL3 regulates Notch signaling in small cell lung cancer","volume":"25","author":"Kim JW","year":"2022","unstructured":"Kim JW, Ko JH, Sage J. DLL3 regulates Notch signaling in small cell lung cancer. iScience. 2022;25(12): Article 105603.","journal-title":"iScience"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-025-00835-2"},{"issue":"40","key":"e_1_3_3_42_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg1850","article-title":"YAP drives fate conversion and chemoresistance of small cell lung cancer","volume":"7","author":"Wu Q","year":"2021","unstructured":"Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C, Fang D, Chen X, Ma L, Xu P, et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 2021;7(40): Article eabg1850.","journal-title":"Sci Adv"},{"issue":"1","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41421-024-00703-x","article-title":"Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer","volume":"10","author":"Jin Y","year":"2024","unstructured":"Jin Y, Wu Y, Reuben A, Zhu L, Gay CM, Wu Q, Zhou X, Mo H, Zheng Q, Ren J, et al. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discov. 2024;10(1):93.","journal-title":"Cell Discov"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.328336.119"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22323"},{"issue":"18","key":"e_1_3_3_46_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185423","article-title":"NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING","volume":"135","author":"Kim YS","year":"2025","unstructured":"Kim YS, Nabet BY, Cortez BN, Sun N-Y, Sebastian R, Redon CE, Ray A, Liu L, Ishola AA, Loew S, et al. NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING. J Clin Invest. 2025;135(18): Article e185423.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.12.004"},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","article-title":"Epigenetic landscape of small cell lung cancer: Small image of a giant recalcitrant disease","volume":"83","author":"Khan P","year":"2020","unstructured":"Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, Salgia R, Batra SK, Nasser MW. Epigenetic landscape of small cell lung cancer: Small image of a giant recalcitrant disease. Semin Cancer Biol. 2020;83:57\u201376.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0718"},{"issue":"4","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117208","article-title":"Regulation of neuronal invasion of small cell lung cancer by STMN2\/\u03b2-alanine-controlled metabolic reprogramming","volume":"45","author":"Zhou Y","year":"2026","unstructured":"Zhou Y, Zhong R, Zhang Y, Shurin MR, Shurin GV, Xiong L, Chu T, Han B, Teng H, Yang Y, et al. Regulation of neuronal invasion of small cell lung cancer by STMN2\/\u03b2-alanine-controlled metabolic reprogramming. Cell Rep. 2026;45(4): Article 117208.","journal-title":"Cell Rep"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-02014-5"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01617-w"},{"issue":"10","key":"e_1_3_3_53_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110490","article-title":"On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm","volume":"38","author":"Conod A","year":"2022","unstructured":"Conod A, Silvano M, Ruiz i Altaba A. On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm. Cell Rep. 2022;38(10): Article 110490.","journal-title":"Cell Rep"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2022.07.006"},{"issue":"6","key":"e_1_3_3_55_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101610","article-title":"Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities","volume":"5","author":"Desai P","year":"2024","unstructured":"Desai P, Takahashi N, Kumar R, Nichols S, Malin J, Hunt A, Schultz C, Cao Y, Tillo D, Nousome D, et al. Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities. Cell Rep Med. 2024;5(6): Article 101610.","journal-title":"Cell Rep Med"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0046-2"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.044"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01058-2"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.08.033"},{"issue":"3","key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ccr.2011.01.036","article-title":"Twist1-induced invadopodia formation promotes tumor metastasis","volume":"19","author":"Eckert MA","year":"2011","unstructured":"Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011;19(3):372\u2013386.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08575-7"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-24-0265"},{"key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2018.04.005","article-title":"Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer","volume":"120","author":"Kimura S","year":"2018","unstructured":"Kimura S, Harada T, Ijichi K, Tanaka K, Liu R, Shibahara D, Kawano Y, Otsubo K, Yoneshima Y, Iwama E, et al. Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. Lung Cancer. 2018;120:98\u2013107.","journal-title":"Lung Cancer"},{"issue":"16","key":"e_1_3_3_64_2","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.3390\/ijms25168748","article-title":"A newly developed anti-L1CAM monoclonal antibody targets small cell lung carcinoma cells","volume":"25","author":"Yamaguchi M","year":"2024","unstructured":"Yamaguchi M, Hirai S, Idogawa M, Sumi T, Uchida H, Sakuma Y. A newly developed anti-L1CAM monoclonal antibody targets small cell lung carcinoma cells. Int J Mol Sci. 2024;25(16):8748.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s42003-025-09440-7","article-title":"Integrated methylome analysis identifies an epigenetically silenced tumor suppressor RASA4 in small cell lung cancer","volume":"9","author":"Fu M","year":"2025","unstructured":"Fu M, Zhu Q, Qi J, Zhang X, Wang Z, Wang J, Huang X, Hu Z, Wang W, Hong B, et al. Integrated methylome analysis identifies an epigenetically silenced tumor suppressor RASA4 in small cell lung cancer. Commun Biol. 2025;9(1):161.","journal-title":"Commun Biol"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0296"},{"issue":"1","key":"e_1_3_3_67_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01695-6","article-title":"MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4\/FOXM1\/RRM2 axis","volume":"22","author":"Khan P","year":"2023","unstructured":"Khan P, Siddiqui JA, Kshirsagar PG, Venkata RC, Maurya SK, Mirzapoiazova T, Perumal N, Chaudhary S, Kanchan RK, Fatima M, et al. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4\/FOXM1\/RRM2 axis. Mol Cancer. 2023;22(1):1.","journal-title":"Mol Cancer"},{"issue":"3","key":"e_1_3_3_68_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.celrep.2016.06.020","article-title":"Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients","volume":"16","author":"Semenova EA","year":"2016","unstructured":"Semenova EA, Kwon M-C, Monkhorst K, Song J-Y, Bhaskaran R, Krijgsman O, Kuilman T, Peters D, Buikhuisen WA, Smit EF, et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients. Cell Rep. 2016;16(3):631\u2013643.","journal-title":"Cell Rep"},{"issue":"1","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1038\/s41467-025-60141-5","article-title":"FOXA2 promotes metastatic competence in small cell lung cancer","volume":"16","author":"Kawasaki K","year":"2025","unstructured":"Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, et al. FOXA2 promotes metastatic competence in small cell lung cancer. Nat Commun. 2025;16(1):4865.","journal-title":"Nat Commun"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-4245"},{"issue":"28","key":"e_1_3_3_71_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220276120","article-title":"EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer","volume":"120","author":"Xiao G-Y","year":"2023","unstructured":"Xiao G-Y, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, et al. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci USA. 2023;120(28): Article e2220276120.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"e_1_3_3_72_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007895","article-title":"Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells","volume":"12","author":"Parodi M","year":"2024","unstructured":"Parodi M, Centonze G, Murianni F, Orecchia P, Andriani F, Roato I, Gardelli C, Balsamo M, Moro M, Tai\u00e8 G, et al. Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells. J Immunother Cancer. 2024;12(3): Article e007895.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1038\/s41467-025-67142-4","article-title":"Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression","volume":"16","author":"Androulidaki A","year":"2025","unstructured":"Androulidaki A, Liu F, Bebber CM, Kisis I, Sakthivelu V, Hunold P, Koerner L, Dahlhaus A, Yapici FI, Grimm C, et al. Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression. Nat Commun. 2025;16(1):11280.","journal-title":"Nat Commun"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.03.005"},{"issue":"1","key":"e_1_3_3_75_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41419-025-07693-y","article-title":"Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression","volume":"16","author":"Alam SK","year":"2025","unstructured":"Alam SK, Pandit A, Wang L, Mortazavi Farsani SS, Thiele BA, Manoj P, Aubry MC, Verma V, Rudin CM, Lo Y-C, et al. Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression. Cell Death Dis. 2025;16(1):370.","journal-title":"Cell Death Dis"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.07.012"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.008"},{"issue":"1","key":"e_1_3_3_78_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41392-023-01725-9","article-title":"New insights into the correlations between circulating tumor cells and target organ metastasis","volume":"8","author":"Zhan Q","year":"2023","unstructured":"Zhan Q, Liu B, Situ X, Luo Y, Fu T, Wang Y, Xie Z, Ren L, Zhu Y, He W, et al. New insights into the correlations between circulating tumor cells and target organ metastasis. Signal Transduct Target Ther. 2023;8(1):465.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00752-0"},{"issue":"1","key":"e_1_3_3_80_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","article-title":"Pre-metastatic niche: Formation, characteristics and therapeutic implication","volume":"9","author":"Wang Y","year":"2024","unstructured":"Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, Yuan W, Gu X, Hu J, Yang S. Pre-metastatic niche: Formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"7069","key":"e_1_3_3_81_2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan RN","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820\u2013827.","journal-title":"Nature"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1101-1194"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1847"},{"issue":"7993","key":"e_1_3_3_84_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-023-06797-9","article-title":"An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis","volume":"625","author":"LaMarche NM","year":"2023","unstructured":"LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature. 2023;625(7993):166\u2013174.","journal-title":"Nature"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.07.001"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature17038"},{"issue":"1","key":"e_1_3_3_87_2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12967-025-06556-6","article-title":"Macrophages in the premetastatic and metastatic niche: Key functions and therapeutic directions","volume":"23","author":"Qi Y","year":"2025","unstructured":"Qi Y, Sun D, Zhai X, Chen F, Niu J, Zhu H. Macrophages in the premetastatic and metastatic niche: Key functions and therapeutic directions. J Transl Med. 2025;23(1):602.","journal-title":"J Transl Med"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01475-4"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06464-z"},{"issue":"1","key":"e_1_3_3_90_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: Latest developments and perspectives","volume":"9","author":"Shi X","year":"2024","unstructured":"Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, Chai Y, Song J, Tang W, Wang X. Mechanism insights and therapeutic intervention of tumor metastasis: Latest developments and perspectives. Signal Transduct Target Ther. 2024;9(1):192.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_3_91_2","article-title":"Mechanisms of small cell lung cancer metastasis","volume":"13","author":"Ko J","year":"2020","unstructured":"Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2020;13(1): Article e13122.","journal-title":"EMBO Mol Med"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.08.013"},{"issue":"1","key":"e_1_3_3_93_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13046-024-03266-7","article-title":"Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer","volume":"44","author":"Lou L","year":"2025","unstructured":"Lou L, Peng K, Ouyang S, Ding W, Mo J, Yan J, Gong X, Liu G, Lu J, Yue P, et al. Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer. J Exp Clin Cancer Res. 2025;44(1):6.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00320-2"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.04.017"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15376"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09492-z"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09434-9"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-023-01241-6"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0134"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0976"},{"issue":"4","key":"e_1_3_3_102_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104514","article-title":"Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer","volume":"10","author":"Csende K","year":"2025","unstructured":"Csende K, Ferencz B, Boettiger K, Pozonec MD, Lantos A, Ferenczy A, Pipek O, Solta A, Ernhofer B, Laszlo V, et al. Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer. ESMO Open. 2025;10(4): Article 104514.","journal-title":"ESMO Open"},{"issue":"1","key":"e_1_3_3_103_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/s41467-022-29517-9","article-title":"Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models","volume":"13","author":"Lissa D","year":"2022","unstructured":"Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun. 2022;13(1):2023.","journal-title":"Nat Commun"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.008"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.003"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0263-0"},{"issue":"1","key":"e_1_3_3_107_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41467-022-28076-3","article-title":"Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells","volume":"13","author":"Borriello L","year":"2022","unstructured":"Borriello L, Coste A, Traub B, Sharma VP, Karagiannis GS, Lin Y, Wang Y, Ye X, Duran CL, Chen X, et al. Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells. Nat Commun. 2022;13(1):626.","journal-title":"Nat Commun"},{"issue":"6","key":"e_1_3_3_108_2","first-page":"2924","article-title":"Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties","volume":"45","author":"Gazdar AF","year":"1985","unstructured":"Gazdar AF, Carney DN, Nau MM, Minna JD. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 1985;45(6):2924\u20132930.","journal-title":"Cancer Res"},{"issue":"6","key":"e_1_3_3_109_2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.21037\/tlcr.2019.11.30","article-title":"Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases","volume":"8","author":"Lohinai Z","year":"2019","unstructured":"Lohinai Z, Megyesfalvi Z, Suda K, Harko T, Ren S, Moldvay J, Laszlo V, Rivard C, Dome B, Hirsch FR. Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. Transl Lung Cancer Res. 2019;8(6):938\u2013950.","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07177-7"},{"issue":"12","key":"e_1_3_3_111_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178540","article-title":"Epigenetic regulation of tumor immunity","volume":"134","author":"Pang L","year":"2024","unstructured":"Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger AB, Chen P. Epigenetic regulation of tumor immunity. J Clin Invest. 2024;134(12): Article e178540.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.10.024"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.021"},{"issue":"1","key":"e_1_3_3_114_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2021.08.763","article-title":"Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers","volume":"17","author":"Qu S","year":"2021","unstructured":"Qu S, Fetsch P, Thomas A, Pommier Y, Schrump DS, Miettinen MM, Chen H. Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers. J Thorac Oncol. 2021;17(1):141\u2013153.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5922"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202208-1471ED"},{"issue":"5","key":"e_1_3_3_117_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115603","article-title":"Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer","volume":"44","author":"Catozzi A","year":"2025","unstructured":"Catozzi A, Peiris Pag\u00e8s M, Humphrey S, Revill M, Morgan D, Roebuck J, Chen Y, Davies-Williams B, Brennan K, Mukarram Hossain ASM, et al. Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer. Cell Rep. 2025;44(5): Article 115603.","journal-title":"Cell Rep"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.009"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.348295.121"},{"issue":"1","key":"e_1_3_3_120_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12943-025-02514-4","article-title":"Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer","volume":"25","author":"Xie M","year":"2025","unstructured":"Xie M, Vuko M, Saran S, Liu S, Chambers AG, Baakza H, Angell HK, Ng F, Gay CM, Cardnell RJ, et al. Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer. Mol Cancer. 2025;25(1):6.","journal-title":"Mol Cancer"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.008"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-023-01210-z"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.027"},{"issue":"43","key":"e_1_3_3_124_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2503387122","article-title":"Lamin A\/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer","volume":"122","author":"Schultz CW","year":"2025","unstructured":"Schultz CW, Saha S, Dhall A, Zhang Y, Desai P, Pongor LS, Scheiblin DA, Magidson V, Shuklah RP, Sebastian R, et al. Lamin A\/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer. Proc Natl Acad Sci USA. 2025;122(43): Article e2503387122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1128"},{"issue":"1","key":"e_1_3_3_126_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-025-67078-9","article-title":"Actin dysregulation induces neuroendocrine plasticity and immune evasion: A vulnerability of small cell lung cancer","volume":"17","author":"Seo Y","year":"2025","unstructured":"Seo Y, Zhang S, Jang J, Ko K-P, Kim K-B, Huang Y, Kim D-W, Kim B, Zou G, Zhang J, et al. Actin dysregulation induces neuroendocrine plasticity and immune evasion: A vulnerability of small cell lung cancer. Nat Commun. 2025;17(1):386.","journal-title":"Nat Commun"},{"issue":"22","key":"e_1_3_3_127_2","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1158\/0008-5472.CAN-25-0405","article-title":"Neuropeptide precursor VGF promotes neuroendocrine differentiation and cancer-associated fibroblast activation in small cell lung cancer","volume":"85","author":"Ding W","year":"2025","unstructured":"Ding W, Zhu J, Mo J, Ouyang S, Liu G, Su Y, Sun D, Ye J, Wu Y, Yan J, et al. Neuropeptide precursor VGF promotes neuroendocrine differentiation and cancer-associated fibroblast activation in small cell lung cancer. Cancer Res. 2025;85(22):4469\u20134484.","journal-title":"Cancer Res"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1267\/ahc.22-00031"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.081"},{"issue":"40","key":"e_1_3_3_130_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq2403","article-title":"POU2AF2\/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity","volume":"8","author":"Szczepanski AP","year":"2022","unstructured":"Szczepanski AP, Tsuboyama N, Watanabe J, Hashizume R, Zhao Z, Wang L. POU2AF2\/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity. Sci Adv. 2022;8(40): Article eabq2403.","journal-title":"Sci Adv"},{"issue":"1","key":"e_1_3_3_131_2","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/s41467-024-46492-5","article-title":"A SWI\/SNF-dependent transcriptional regulation mediated by POU2AF2\/C11orf53 at enhancer","volume":"15","author":"Szczepanski A","year":"2024","unstructured":"Szczepanski A, Tsuboyama N, Lyu H, Wang P, Beytullahoglu O, Zhang T, Singer BD, Yue F, Zhao Z, Wang L. A SWI\/SNF-dependent transcriptional regulation mediated by POU2AF2\/C11orf53 at enhancer. Nat Commun. 2024;15(1):2067.","journal-title":"Nat Commun"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.012"},{"issue":"12","key":"e_1_3_3_133_2","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.jtho.2020.07.008","article-title":"The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: A brief report","volume":"15","author":"Pearsall SM","year":"2020","unstructured":"Pearsall SM, Humphrey S, Revill M, Morgan D, Frese KK, Galvin M, Kerr A, Carter M, Priest L, Blackhall F, et al. The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: A brief report. J Thorac Oncol. 2020;15(12):1836\u20131843.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00945-y"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13078"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2360"},{"issue":"8","key":"e_1_3_3_137_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103730","article-title":"YAP1 defines an emergent, plastic population of relapsed small cell lung cancer","volume":"21","author":"Stewart CA","year":"2026","unstructured":"Stewart CA, Ramkumar K, Wang R, Xi Y, Halliday A, Diao L, Wang Q, Serrano A, Groves S, Heeke S, et al. YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. J Thorac Oncol. 2026;21(8): Article 103730.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"e_1_3_3_138_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay CM","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346\u2013360.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.010"},{"key":"e_1_3_3_140_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108048","article-title":"Spatial proteomic profiling reveals conserved prognostic immune microenvironment features across molecular subtypes in small cell lung cancer","volume":"222","author":"Zhai M","year":"2025","unstructured":"Zhai M, Zhang Z, Dong J, Li Z, Cao Y, Chen R, Zhou M, Yang L. Spatial proteomic profiling reveals conserved prognostic immune microenvironment features across molecular subtypes in small cell lung cancer. Pharmacol Res. 2025;222: Article 108048.","journal-title":"Pharmacol Res"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.05.001"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0104"},{"key":"e_1_3_3_143_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115067","article-title":"The tumor immune microenvironment of SCLC is not associated with its molecular subtypes","volume":"212","author":"Velut Y","year":"2024","unstructured":"Velut Y, Arqu\u00e9 B, Wislez M, Blons H, Burroni B, Prieto M, Beau S, Fournel L, Birsen G, Cremer I, et al. The tumor immune microenvironment of SCLC is not associated with its molecular subtypes. Eur J Cancer. 2024;212: Article 115067.","journal-title":"Eur J Cancer"},{"issue":"50","key":"e_1_3_3_144_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp8674","article-title":"Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma","volume":"8","author":"Gopal P","year":"2022","unstructured":"Gopal P, Petty A, Rogacki K, Bera T, Bareja R, Peacock CD, Abazeed ME. Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma. Sci Adv. 2022;8(50): Article eabp8674.","journal-title":"Sci Adv"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02343-7"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0020-z"},{"key":"e_1_3_3_147_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105515","article-title":"ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A\u22170201","volume":"112","author":"Yuan L","year":"2025","unstructured":"Yuan L, Li S, Zhu Y, Yang L, Zhang X, Qu Y, Wang Z, Duan J, Zhong J, Tian Y, et al. ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A\u22170201. EBioMedicine. 2025;112: Article 105515.","journal-title":"EBioMedicine"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.001"},{"issue":"1","key":"e_1_3_3_149_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12967-026-07940-6","article-title":"Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer","volume":"24","author":"Huang J","year":"2026","unstructured":"Huang J, Zhang Z, Cai G, Huang W, Chen Y-Q, Zhang J, Yang L, Zhou Q, Yang J-J, Wang J. Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer. J Transl Med. 2026;24(1):358.","journal-title":"J Transl Med"},{"issue":"1","key":"e_1_3_3_150_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13073-025-01526-5","article-title":"Deep learning-based histomorphological subtyping and risk stratification of small cell lung cancer from hematoxylin and eosin-stained whole slide images","volume":"17","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Liu S, Chen J, Chen R, Yang Z, Sheng R, Li X, Wang T, Liu H, Yang F, et al. Deep learning-based histomorphological subtyping and risk stratification of small cell lung cancer from hematoxylin and eosin-stained whole slide images. Genome Med. 2025;17(1):98.","journal-title":"Genome Med"},{"issue":"8015","key":"e_1_3_3_151_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41586-024-07441-w","article-title":"A whole-slide foundation model for digital pathology from real-world data","volume":"630","author":"Xu H","year":"2024","unstructured":"Xu H, Usuyama N, Bagga J, Zhang S, Rao R, Naumann T, Wong C, Gero Z, Gonz\u00e1lez J, Gu Y, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181\u2013188.","journal-title":"Nature"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.012"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00996-1"},{"key":"e_1_3_3_154_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101215","article-title":"Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs","volume":"81","author":"Dong S","year":"2025","unstructured":"Dong S, Li X, Huang Q, Li Y, Li J, Zhu X, Xue C, Chen R, Zeng Y, Wu J, et al. Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resist Updat. 2025;81: Article 101215.","journal-title":"Drug Resist Updat"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00803-0"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0340-z"},{"issue":"4","key":"e_1_3_3_157_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41388-024-03202-1","article-title":"Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15","volume":"44","author":"Niu Y","year":"2024","unstructured":"Niu Y, Tang Y, Ma F, Zhou X, Chen Y, Wang Y, Xu Y, Sun L, Liang S, Yang J, et al. Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15. Oncogene. 2024;44(4):255\u2013268.","journal-title":"Oncogene"},{"issue":"1","key":"e_1_3_3_158_2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s42003-021-01842-7","article-title":"Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer","volume":"4","author":"Cai L","year":"2021","unstructured":"Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, Li Y, Zhang Y-A, Deb D, Stastny V, et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021;4(1):314.","journal-title":"Commun Biol"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00595-y"},{"issue":"3","key":"e_1_3_3_160_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/cas.15653","article-title":"Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation","volume":"114","author":"Liang S","year":"2022","unstructured":"Liang S, Wang Q, Wen Y, Wang Y, Li M, Wang Q, Peng J, Guo L. Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation. Cancer Sci. 2022;114(3):921\u2013936.","journal-title":"Cancer Sci"},{"issue":"8","key":"e_1_3_3_161_2","first-page":"4006","article-title":"Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling","volume":"130","author":"Cochrane CR","year":"2020","unstructured":"Cochrane CR, Vaghjiani V, Szczepny A, Jayasekara WSN, Gonzalez-Rajal A, Kikuchi K, McCaughan GW, Burgess A, Gough DJ, Watkins DN, et al. Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling. J Clin Invest. 2020;130(8):4006\u20134018.","journal-title":"J Clin Invest"},{"issue":"5","key":"e_1_3_3_162_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.12.102","article-title":"The impact of targeting TRAF2 and NCK-interacting protein kinase on antitumor effect and tumor immune environment in c-MYC-high SCLC","volume":"21","author":"Tanimoto A","year":"2025","unstructured":"Tanimoto A, Ramkumar K, Stewart CA, Zhang B, Concannon K, Cardnell RJ, Shen L, Wang Q, Wang J, Gay CM, et al. The impact of targeting TRAF2 and NCK-interacting protein kinase on antitumor effect and tumor immune environment in c-MYC-high SCLC. J Thorac Oncol. 2025;21(5): Article 103543.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3844"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02204-3"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02226-x"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.04.012"},{"issue":"1","key":"e_1_3_3_167_2","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41467-026-69262-x","article-title":"Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC","volume":"17","author":"Chakraborty S","year":"2026","unstructured":"Chakraborty S, Elliott A, Sen U, Coleman C, Jethalia V, Ventura K, Fan C-W, Sritharan R, Banerjee A, Mahendravarman Y, et al. Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC. Nat Commun. 2026;17(1):2597.","journal-title":"Nat Commun"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0112"},{"issue":"2","key":"e_1_3_3_169_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly FJ","year":"2022","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2022;23(2):78\u201394.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_3_170_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jare.2023.12.020","article-title":"HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy","volume":"66","author":"Shen W","year":"2023","unstructured":"Shen W, Lyu Q, Yi R, Sun Y, Zhang W, Wei T, Zhang Y, Shi J, Zhang J. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy. J Adv Res. 2023;66:165\u2013180.","journal-title":"J Adv Res"},{"issue":"2","key":"e_1_3_3_171_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner EE","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31(2):286\u2013299.","journal-title":"Cancer Cell"},{"issue":"1","key":"e_1_3_3_172_2","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1038\/s41467-026-75117-2","article-title":"Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer","volume":"17","author":"Best S","year":"2026","unstructured":"Best S, Hippe DS, Grunblatt E, Fatherree J, Chanana P, Wu F, Ivey R, Kennedy JJ, Sokolov D, Ibrahim A, et al. Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer. Nat Commun. 2026;17(1):8402.","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_3_3_173_2","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1038\/s41467-018-06162-9","article-title":"Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer","volume":"9","author":"Wagner AH","year":"2018","unstructured":"Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun. 2018;9(1):3787.","journal-title":"Nat Commun"},{"issue":"6","key":"e_1_3_3_174_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1541-7786.MCR-24-0652","article-title":"KSR1 mediates small cell lung carcinoma tumor initiation and cisplatin resistance","volume":"23","author":"Chatterjee D","year":"2025","unstructured":"Chatterjee D, Svoboda RA, Huisman DH, Drapkin BJ, Vieira HM, Rao C, Askew JW, Fisher KW, Lewis RE. KSR1 mediates small cell lung carcinoma tumor initiation and cisplatin resistance. Mol Cancer Res. 2025;23(6):553\u2013566.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"e_1_3_3_175_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/1078-0432.CCR-21-1943","article-title":"Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer","volume":"28","author":"Jin Y","year":"2021","unstructured":"Jin Y, Chen Y, Tang H, Hu X, Hubert SM, Li Q, Su D, Xu H, Fan Y, Yu X, et al. Activation of PI3K\/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin Cancer Res. 2021;28(3):526\u2013539.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.06.012"},{"issue":"7","key":"e_1_3_3_177_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102194","article-title":"MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer","volume":"6","author":"Del Rey-Vergara R","year":"2025","unstructured":"Del Rey-Vergara R, Galindo-Campos MA, Rocha P, Carpes M, Mart\u00ednez C, Masfarr\u00e9 L, Men\u00e9ndez S, Quimis F, Rossell A, I\u00f1a\u00f1ez A, et al. MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer. Cell Rep Med. 2025;6(7): Article 102194.","journal-title":"Cell Rep Med"},{"issue":"1","key":"e_1_3_3_178_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41419-025-08102-0","article-title":"S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer","volume":"16","author":"Charan M","year":"2025","unstructured":"Charan M, Mishra S, Shilo K, Zhang X, Verma AK, Ghanta P, Webb A, Ganju RK. S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer. Cell Death Dis. 2025;16(1):774.","journal-title":"Cell Death Dis"},{"issue":"6","key":"e_1_3_3_179_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41388-022-02558-6","article-title":"Targeting PEA3 transcription factors to mitigate small cell lung cancer progression","volume":"42","author":"Shia DW","year":"2022","unstructured":"Shia DW, Choi W, Vijayaraj P, Vuong V, Sandlin JM, Lu MM, Aziz A, Marin C, Aros CJ, Sen C, et al. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression. Oncogene. 2022;42(6):434\u2013448.","journal-title":"Oncogene"},{"issue":"1","key":"e_1_3_3_180_2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/s41467-026-69899-8","article-title":"Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis","volume":"17","author":"Peng H","year":"2026","unstructured":"Peng H, Wang Z, Wang M, Ding Z, Li K, Wang Y, Yu X, Song S, Deng Y, Liu Y, et al. Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nat Commun. 2026;17(1):2048.","journal-title":"Nat Commun"},{"issue":"4","key":"e_1_3_3_181_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/CAD.0000000000001683","article-title":"Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy","volume":"36","author":"Shen Y","year":"2025","unstructured":"Shen Y, Jiang Y, Wu J, Wang C, Huang JBK, Liu J, Chen S. Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy. Anti-Cancer Drugs. 2025;36(4):290\u2013296.","journal-title":"Anti-Cancer Drugs"},{"key":"e_1_3_3_182_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01059-1"},{"issue":"9","key":"e_1_3_3_183_2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","article-title":"Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation","volume":"18","author":"Rudin CM","year":"2023","unstructured":"Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, et al. Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J Thorac Oncol. 2023;18(9):1222\u20131232.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_184_2","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1038\/s41467-025-66800-x","article-title":"ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer","volume":"16","author":"Meder L","year":"2025","unstructured":"Meder L, Orschel CI, Bouchez CL, Gholamipoorfard R, Orschel CV, Stahl D, Kreer C, Koker M, Nill M, Kocak IG, et al. ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Nat Commun. 2025;16(1):10983.","journal-title":"Nat Commun"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03390-5"},{"key":"e_1_3_3_186_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218160","article-title":"Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression","volume":"638","author":"Khan MA","year":"2025","unstructured":"Khan MA, Khan P, Fatima M, Rehman AU, Anwar L, Alsafwani ZW, Ahmad A, Abbas Zaidi MA, Cox JL, Zahid A, et al. Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. Cancer Lett. 2025;638: Article 218160.","journal-title":"Cancer Lett"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02821-5"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01872-3"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-026-03798-6"},{"issue":"1","key":"e_1_3_3_190_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-026-02644-1","article-title":"BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1\/2-cyclin D1\/CDK4\/6 axis","volume":"11","author":"Wu T","year":"2026","unstructured":"Wu T, Qi S, Shi C, Wu C, Liu Q, Hu C, Hu J, Wang A, Liu J, Qi Z, et al. BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1\/2-cyclin D1\/CDK4\/6 axis. Signal Transduct Target Ther. 2026;11(1):125.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.043"},{"key":"e_1_3_3_192_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204469"},{"issue":"2","key":"e_1_3_3_193_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.canlet.2015.12.001","article-title":"Bromodomain and hedgehog pathway targets in small cell lung cancer","volume":"371","author":"Kaur G","year":"2015","unstructured":"Kaur G, Reinhart RA, Monks A, Evans D, Morris J, Polley E, Teicher BA. Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Lett. 2015;371(2):225\u2013239.","journal-title":"Cancer Lett"},{"key":"e_1_3_3_194_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0913"},{"key":"e_1_3_3_195_2","doi-asserted-by":"crossref","first-page":"1563992","DOI":"10.3389\/fimmu.2025.1563992","article-title":"Multiscale information processing in the immune system","volume":"16","author":"Navarro Quiroz R","year":"2025","unstructured":"Navarro Quiroz R, Villarreal Camacho J, Zarate Pe\u00f1ata E, Bello Lemus Y, L\u00f3pez-Fern\u00e1ndez C, Gomez Escorcia L, Fern\u00e1ndez-Ponce C, Rebolledo Cobos M, Fandi\u00f1o Moreno J, Fiorillo-Moreno O, et al. Multiscale information processing in the immune system. Front Immunol. 2025;16:1563992.","journal-title":"Front Immunol"},{"issue":"1","key":"e_1_3_3_196_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang Q","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, Li X, Dong S, Dong Z, Hu S. Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther. 2025;10(1):186.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_197_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09539-1"},{"key":"e_1_3_3_198_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02113-x"},{"issue":"6","key":"e_1_3_3_199_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu SV","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro CJ, Califano R, Nishio M, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u2013630.","journal-title":"J Clin Oncol"},{"issue":"10212","key":"e_1_3_3_200_2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares L","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u20131939.","journal-title":"Lancet"},{"key":"e_1_3_3_201_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02176-w"},{"key":"e_1_3_3_202_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.02.008"},{"issue":"8046","key":"e_1_3_3_203_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41586-024-08257-4","article-title":"Cancer cells impair monocyte-mediated T cell stimulation to evade immunity","volume":"637","author":"Elewaut A","year":"2024","unstructured":"Elewaut A, Estivill G, Bayerl F, Castillon L, Novatchkova M, Pottendorfer E, Hoffmann-Haas L, Sch\u00f6nlein M, Nguyen TV, Lauss M, et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature. 2024;637(8046):716\u2013725.","journal-title":"Nature"},{"key":"e_1_3_3_204_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02219-2"},{"key":"e_1_3_3_205_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01443-y"},{"key":"e_1_3_3_206_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09188-4"},{"key":"e_1_3_3_207_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2"},{"issue":"4","key":"e_1_3_3_208_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013867","article-title":"Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4+ neutrophils and S100A8+ monocytes","volume":"14","author":"Zeng P","year":"2026","unstructured":"Zeng P, Li H-F, Shu W-B, Zhang J, Zhao T-C, Hu J-W, Wang J-F, Wang C, Lu Q-Y, Yang J-H, et al. Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4+ neutrophils and S100A8+ monocytes. J Immunother Cancer. 2026;14(4): Article e013867.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_209_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02233-4"},{"issue":"43","key":"e_1_3_3_210_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss L","year":"2020","unstructured":"Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, Pal R, Yuan M, Asara J, Patsoukis N, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43): Article eaay1863.","journal-title":"Sci Immunol"},{"issue":"6745","key":"e_1_3_3_211_2","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr3026","article-title":"Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity","volume":"388","author":"Chiu DK-C","year":"2025","unstructured":"Chiu DK-C, Zhang X, Cheng BY-L, Liu Q, Hayashi K, Yu B, Lee R, Zhang C, An X, Rajadas J, et al. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science. 2025;388(6745): Article eadr3026.","journal-title":"Science"},{"key":"e_1_3_3_212_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.021"},{"key":"e_1_3_3_213_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.017"},{"key":"e_1_3_3_214_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.06.006"},{"issue":"87","key":"e_1_3_3_215_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg1487","article-title":"Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response","volume":"8","author":"Dykema AG","year":"2023","unstructured":"Dykema AG, Zhang J, Cheung LS, Connor S, Zhang B, Zeng Z, Cherry CM, Li T, Caushi JX, Nishimoto M, et al. Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response. Sci Immunol. 2023;8(87): Article eadg1487.","journal-title":"Sci Immunol"},{"key":"e_1_3_3_216_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00832-9"},{"key":"e_1_3_3_217_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.07.011"},{"key":"e_1_3_3_218_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1042"},{"issue":"95","key":"e_1_3_3_219_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade2094","article-title":"Intratumoral antigen signaling traps CD8+ T cells to confine exhaustion to the tumor site","volume":"9","author":"Takahashi M","year":"2024","unstructured":"Takahashi M, So TY, Chamberlain-Evans V, Hughes R, Yam-Puc JC, Kania K, Ruhle M, Mann T, Schuijs MJ, Coupland P, et al. Intratumoral antigen signaling traps CD8+ T cells to confine exhaustion to the tumor site. Sci Immunol. 2024;9(95): Article eade2094.","journal-title":"Sci Immunol"},{"key":"e_1_3_3_220_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.004"},{"key":"e_1_3_3_221_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01017-z"},{"key":"e_1_3_3_222_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02144-4"},{"key":"e_1_3_3_223_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00786-4"},{"key":"e_1_3_3_224_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08439-0"},{"key":"e_1_3_3_225_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0199"},{"issue":"17","key":"e_1_3_3_226_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq7084","article-title":"In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer","volume":"11","author":"Brumage L","year":"2025","unstructured":"Brumage L, Best S, Hippe DS, Grunblatt E, Chanana P, Wu F, Lee MC, Ying Z, Ibrahim A, Chung JH, et al. In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer. Sci Adv. 2025;11(17): Article eadq7084.","journal-title":"Sci Adv"},{"issue":"3","key":"e_1_3_3_227_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00432-025-06164-3","article-title":"Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism","volume":"151","author":"Zhao Q-Y","year":"2025","unstructured":"Zhao Q-Y, Liu W-J, Wang J-G, Li H, Lv J-L, Wang Y, Wang C. Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism. J Cancer Res Clin Oncol. 2025;151(3):126.","journal-title":"J Cancer Res Clin Oncol"},{"key":"e_1_3_3_228_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00800-3"},{"key":"e_1_3_3_229_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06483-w"},{"key":"e_1_3_3_230_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09202-9"},{"key":"e_1_3_3_231_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.08.008"},{"issue":"1","key":"e_1_3_3_232_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccell.2024.11.003","article-title":"Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity","volume":"43","author":"Qiu Y","year":"2024","unstructured":"Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, Pan X, Wang Z, Chen DG, Zhu H, et al. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer Cell. 2024;43(1):103\u2013121.e8.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_233_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02178-8"},{"key":"e_1_3_3_234_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011"},{"issue":"34","key":"e_1_3_3_235_2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202413608","article-title":"The LDH-H3K18La-Nur77 axis potentiates immune escape in small cell lung cancer","volume":"12","author":"Shang X","year":"2025","unstructured":"Shang X, Cheng B, Zhang C, Zhao C, Wang R, Zhang X, Jiang D, Zhang X, Ma X, Mao H, et al. The LDH-H3K18La-Nur77 axis potentiates immune escape in small cell lung cancer. Adv Sci. 2025;12(34): Article e13608.","journal-title":"Adv Sci"},{"issue":"7","key":"e_1_3_3_236_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143729","article-title":"Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells","volume":"131","author":"Liikanen I","year":"2021","unstructured":"Liikanen I, Lauhan C, Quon S, Omilusik K, Phan AT, Bartrol\u00ed LB, Ferry A, Goulding J, Chen J, Scott-Browne JP, et al. Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021;131(7): Article e143729.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_237_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.07.017"},{"issue":"1","key":"e_1_3_3_238_2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1186\/s12967-024-05926-w","article-title":"Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis","volume":"22","author":"Zhu H","year":"2024","unstructured":"Zhu H, Shi H, Lu J, Zhu K, Yang L, Guo L, Tang L, Shi Y, Hu X. Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis. J Transl Med. 2024;22(1):1117.","journal-title":"J Transl Med"},{"key":"e_1_3_3_239_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08258-3"},{"key":"e_1_3_3_240_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578033","article-title":"Dynamics of cachexia-associated inflammatory changes in the brain accompanying intra-abdominal fibrosarcoma growth in Wistar rats","volume":"376","author":"Cernackova A","year":"2023","unstructured":"Cernackova A, Tillinger A, Bizik J, Mravec B, Horvathova L. Dynamics of cachexia-associated inflammatory changes in the brain accompanying intra-abdominal fibrosarcoma growth in Wistar rats. J Neuroimmunol. 2023;376: Article 578033.","journal-title":"J Neuroimmunol"},{"key":"e_1_3_3_241_2","doi-asserted-by":"crossref","first-page":"1439877","DOI":"10.3389\/fimmu.2024.1439877","article-title":"Unraveling the obesity paradox in small cell lung cancer immunotherapy: Unveiling prognostic insights through body composition analysis","volume":"15","author":"Fang R","year":"2024","unstructured":"Fang R, Yan L, Xu S, Xu Y, Gan T, Gong J, Zhang J, Xie C, Liao Z. Unraveling the obesity paradox in small cell lung cancer immunotherapy: Unveiling prognostic insights through body composition analysis. Front Immunol. 2024;15:1439877.","journal-title":"Front Immunol"},{"key":"e_1_3_3_242_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01287-w"},{"key":"e_1_3_3_243_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-025-02769-1"},{"key":"e_1_3_3_244_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01338-2"},{"issue":"3","key":"e_1_3_3_245_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108296","article-title":"SCLC-CellMiner: A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures","volume":"33","author":"Tlemsani C","year":"2020","unstructured":"Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman KE, Roper N, Varma S, Luna A, Rajapakse VN, Sebastian R, et al. SCLC-CellMiner: A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures. Cell Rep. 2020;33(3): Article 108296.","journal-title":"Cell Rep"},{"key":"e_1_3_3_246_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00854-6"},{"key":"e_1_3_3_247_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01678-9"},{"issue":"10","key":"e_1_3_3_248_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.101065","article-title":"State-of-the-art and future directions in structural proteomics","volume":"24","author":"Happonen LJ","year":"2025","unstructured":"Happonen LJ, Varjosalo M. State-of-the-art and future directions in structural proteomics. Mol Cell Proteomics. 2025;24(10): Article 101065.","journal-title":"Mol Cell Proteomics"},{"issue":"31","key":"e_1_3_3_249_2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402716","article-title":"Spatial transcriptome-wide profiling of small cell lung cancer reveals intra-tumoral molecular and subtype heterogeneity","volume":"11","author":"Zhang Z","year":"2024","unstructured":"Zhang Z, Sun X, Liu Y, Zhang Y, Yang Z, Dong J, Wang N, Ying J, Zhou M, Yang L. Spatial transcriptome-wide profiling of small cell lung cancer reveals intra-tumoral molecular and subtype heterogeneity. Adv Sci. 2024;11(31): Article e2402716.","journal-title":"Adv Sci"},{"key":"e_1_3_3_250_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08834-1"},{"key":"e_1_3_3_251_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.09.006"},{"key":"e_1_3_3_252_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.042"},{"issue":"7","key":"e_1_3_3_253_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s42256-025-01052-4","article-title":"Integrating multimodal cancer data using deep latent variable path modelling","volume":"7","author":"Ing A","year":"2025","unstructured":"Ing A, Andrades A, Cosenza MR, Korbel JO. Integrating multimodal cancer data using deep latent variable path modelling. Nat Mach Intell. 2025;7(7):1053\u20131075.","journal-title":"Nat Mach Intell"},{"key":"e_1_3_3_254_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.06.005"},{"key":"e_1_3_3_255_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00723-5"},{"key":"e_1_3_3_256_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.008"},{"issue":"6","key":"e_1_3_3_257_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/PAS.0000000000001444","article-title":"Insulinoma-associated protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56","volume":"44","author":"Sakakibara R","year":"2020","unstructured":"Sakakibara R, Kobayashi M, Takahashi N, Inamura K, Ninomiya H, Wakejima R, Kitazono S, Yanagitani N, Horiike A, Ichinose J, et al. Insulinoma-associated protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56. Am J Surg Pathol. 2020;44(6):757\u2013764.","journal-title":"Am J Surg Pathol"},{"key":"e_1_3_3_258_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.06.004"},{"issue":"6","key":"e_1_3_3_259_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.6004\/jnccn.2006.0052","article-title":"Paraneoplastic syndromes associated with small cell lung cancer","volume":"4","author":"Gandhi L","year":"2006","unstructured":"Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Cancer Netw. 2006;4(6):631\u2013638.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"e_1_3_3_260_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2967\/jnumed.125.270233","article-title":"Malignancy detection rates of [68Ga]Ga-SSO120 PET\/CT in patients with small cell lung cancer and large cell neuroendocrine lung cancer","volume":"67","author":"Christensen TN","year":"2026","unstructured":"Christensen TN, Langer SW, Dejanovic D, Gillings N, Madsen J, Persson G, Keller SH, Albrecht-Beste E, Fischer BM. Malignancy detection rates of [68Ga]Ga-SSO120 PET\/CT in patients with small cell lung cancer and large cell neuroendocrine lung cancer. J Nucl Med. 2026;67(4):506\u2013513.","journal-title":"J Nucl Med"},{"issue":"16","key":"e_1_3_3_261_2","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2004.11.089","article-title":"Positron emission tomography in limited-stage small-cell lung cancer: A prospective study","volume":"22","author":"Bradley JD","year":"2004","unstructured":"Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: A prospective study. J Clin Oncol. 2004;22(16):3248\u20133254.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_262_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2013.0012","article-title":"Modern staging of small cell lung cancer","volume":"11","author":"Kalemkerian GP","year":"2013","unstructured":"Kalemkerian GP, Gadgeel SM. Modern staging of small cell lung cancer. J Natl Compr Cancer Netw. 2013;11(1):99\u2013104.","journal-title":"J Natl Compr Cancer Netw"},{"key":"e_1_3_3_263_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-00991-6"},{"key":"e_1_3_3_264_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00917-2"},{"issue":"16","key":"e_1_3_3_265_2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70050","article-title":"Artificial intelligence across the cancer care continuum","volume":"131","author":"Riaz IB","year":"2025","unstructured":"Riaz IB, Khan MA, Osterman TJ. Artificial intelligence across the cancer care continuum. Cancer. 2025;131(16): Article e70050.","journal-title":"Cancer"},{"issue":"10","key":"e_1_3_3_266_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.6004\/jnccn.2011.0094","article-title":"Surgery for early-stage small cell lung cancer","volume":"9","author":"Schneider BJ","year":"2011","unstructured":"Schneider BJ, Saxena A, Downey RJ. Surgery for early-stage small cell lung cancer. J Natl Compr Cancer Netw. 2011;9(10):1132\u20131139.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"23","key":"e_1_3_3_267_2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon JP","year":"1992","unstructured":"Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618\u20131624.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_3_268_2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1470-2045(13)70511-4","article-title":"Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): A randomised phase 3 study","volume":"15","author":"Kubota K","year":"2013","unstructured":"Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): A randomised phase 3 study. Lancet Oncol. 2013;15(1):106\u2013113.","journal-title":"Lancet Oncol"},{"issue":"8","key":"e_1_3_3_269_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn C","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116\u20131125.","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_3_3_270_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41421-025-00838-5","article-title":"Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I\u2013III small-cell lung cancer: A phase 2 trial (LungMate-005)","volume":"11","author":"Sun F","year":"2025","unstructured":"Sun F, Zhang L, Sun L, Wang D, Song N, Duan L, Bian D, Hu J, Yan Y, Yang J, et al. Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I\u2013III small-cell lung cancer: A phase 2 trial (LungMate-005). Cell Discov. 2025;11(1):95.","journal-title":"Cell Discov"},{"issue":"10","key":"e_1_3_3_271_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2015.63.8171","article-title":"Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer","volume":"34","author":"Yang C-FJ","year":"2016","unstructured":"Yang C-FJ, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, Onaitis MW, Tong BC, D\u2019Amico TA, Berry MF, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34(10):1057\u20131064.","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_3_272_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans WK","year":"1985","unstructured":"Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3(11):1471\u20131477.","journal-title":"J Clin Oncol"},{"issue":"14","key":"e_1_3_3_273_2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng Y","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313\u20131327.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_3_274_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105071","article-title":"Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial","volume":"10","author":"Garassino MC","year":"2025","unstructured":"Garassino MC, Khalifa J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis DL, Migliorino MR, et al. Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial. ESMO Open. 2025;10(6): Article 105071.","journal-title":"ESMO Open"},{"issue":"5","key":"e_1_3_3_275_2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdq576","article-title":"Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)","volume":"22","author":"Le P\u00e9choux C","year":"2011","unstructured":"Le P\u00e9choux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, Keus R, Hatton M, Videtic GM, Senan S, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol. 2011;22(5):1154\u20131163.","journal-title":"Ann Oncol"},{"issue":"6","key":"e_1_3_3_276_2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70351","article-title":"Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial","volume":"132","author":"Song C","year":"2026","unstructured":"Song C, Zhao X, Li S, Guo X, Zhang X, Wang X, Li Y, Yan K, Su J, Xu J, et al. Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial. Cancer. 2026;132(6): Article e70351.","journal-title":"Cancer"},{"issue":"23","key":"e_1_3_3_277_2","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","article-title":"Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer","volume":"22","author":"Fried DB","year":"2004","unstructured":"Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837\u20134845.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_278_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-026-02668-7","article-title":"Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): A phase II clinical trial","volume":"11","author":"Zhao Q","year":"2026","unstructured":"Zhao Q, Li Y, Zhang H, Han D, Kan Y, Sun H, Liu C, Wang L, Han X, Hua Y, et al. Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): A phase II clinical trial. Signal Transduct Target Ther. 2026;11(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"e_1_3_3_279_2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ijrobp.2003.10.021","article-title":"70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukemia Group B study 39808","volume":"59","author":"Bogart JA","year":"2004","unstructured":"Bogart JA, Herndon JE, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59(2):460\u2013468.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"e_1_3_3_280_2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins KA","year":"2026","unstructured":"Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, et al. Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology\/Alliance LU005. J Clin Oncol. 2026;44(8):630\u2013640.","journal-title":"J Clin Oncol"},{"issue":"13","key":"e_1_3_3_281_2","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart J","year":"2023","unstructured":"Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538. J Clin Oncol. 2023;41(13):2394\u20132402.","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_3_282_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijrobp.2025.09.058","article-title":"Simultaneous integrated dose reduction radiation therapy versus conventional fractionated radiation therapy with chemotherapy for limited-stage small cell lung cancer in the modern treatment era: A phase 3, randomized clinical trial (SDR-RT trial)","volume":"124","author":"Zhan T-Y","year":"2026","unstructured":"Zhan T-Y, Zhang T, Wang W-Q, Deng L, Zhai Y-R, Yan W-B, Wang X, Wang J-Y, Liu W-Y, Li M-H, et al. Simultaneous integrated dose reduction radiation therapy versus conventional fractionated radiation therapy with chemotherapy for limited-stage small cell lung cancer in the modern treatment era: A phase 3, randomized clinical trial (SDR-RT trial). Int J Radiat Oncol Biol Phys. 2026;124(3):692\u2013701.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"e_1_3_3_283_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0360-3016(02)04493-0","article-title":"Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer","volume":"56","author":"Miller KL","year":"2003","unstructured":"Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;56(2):355\u2013359.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"e_1_3_3_284_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg BH","year":"2021","unstructured":"Gr\u00f8nberg BH, Killingberg KT, Fl\u00f8tten \u00d8, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(3):321\u2013331.","journal-title":"Lancet Oncol"},{"issue":"10","key":"e_1_3_3_285_2","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdw263","article-title":"Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: Usefulness of the individual patient data meta-analysis","volume":"27","author":"De Ruysscher D","year":"2016","unstructured":"De Ruysscher D, Lueza B, Le P\u00e9choux C, Johnson DH, O\u2019Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: Usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818\u20131828.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_286_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1199"},{"issue":"2","key":"e_1_3_3_287_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth BJ","year":"1992","unstructured":"Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10(2):282\u2013291.","journal-title":"J Clin Oncol"},{"issue":"2","key":"e_1_3_3_288_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda K","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85\u201391.","journal-title":"N Engl J Med"},{"issue":"15","key":"e_1_3_3_289_2","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara PN","year":"2009","unstructured":"Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, et al. Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530\u20132535.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_290_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.8595"},{"issue":"26","key":"e_1_3_3_291_2","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2007.15.7545","article-title":"Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial","volume":"26","author":"Hermes A","year":"2008","unstructured":"Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstr\u00f8m S, Thaning L, Vilsvik J, Aaseb\u00f8 U, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. J Clin Oncol. 2008;26(26):4261\u20134267.","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_3_292_2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1200\/JCO.1987.5.11.1731","article-title":"A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group","volume":"5","author":"Johnson DH","year":"1987","unstructured":"Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, Omura G, Greco FA. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987;5(11):1731\u20131738.","journal-title":"J Clin Oncol"},{"issue":"10","key":"e_1_3_3_293_2","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1200\/JCO.1994.12.10.2022","article-title":"Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer","volume":"12","author":"Ihde DC","year":"1994","unstructured":"Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12(10):2022\u20132034.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_3_294_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams WT","year":"2020","unstructured":"Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300\u2013312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"e_1_3_3_295_2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn L","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20132229.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_3_296_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman JW","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51\u201365.","journal-title":"Lancet Oncol"},{"issue":"12","key":"e_1_3_3_297_2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng Y","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u20131232.","journal-title":"JAMA"},{"issue":"6","key":"e_1_3_3_298_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang J","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u2013747.","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_3_3_299_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: The phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng Y","year":"2025","unstructured":"Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, Bi M, Fu X, Li C, Lv D, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: The phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol. 2025;11(1):16\u201325.","journal-title":"JAMA Oncol"},{"issue":"7","key":"e_1_3_3_300_2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng Y","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19(7):1073\u20131085.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_301_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-024-02115-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer","volume":"10","author":"Chen Z","year":"2025","unstructured":"Chen Z, Chen J, Huang D, Zhang W, Wu L, Yi T, Wang Q, Han L, Tan L, Li Y, et al. A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer. Signal Transduct Target Ther. 2025;10(1):28.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"e_1_3_3_302_2","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial","volume":"30","author":"Cheng Y","year":"2024","unstructured":"Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, Huang C, Wei S, Sun H, Li X, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial. Nat Med. 2024;30(10):2967\u20132976.","journal-title":"Nat Med"},{"issue":"12","key":"e_1_3_3_303_2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35938","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"131","author":"Leal TA","year":"2025","unstructured":"Leal TA, Wang Y, Dowlati A, Chay CH, Chen Y, Mohindra AR, Razaq M, Ajuja HG, Liu J, King DM, et al. Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Cancer. 2025;131(12): Article e35938.","journal-title":"Cancer"},{"issue":"12","key":"e_1_3_3_304_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S2213-2600(25)00240-1","article-title":"Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): A single-arm phase 2 trial","volume":"13","author":"Asao T","year":"2025","unstructured":"Asao T, Saida Y, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, et al. Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): A single-arm phase 2 trial. Lancet Respir Med. 2025;13(12):1057\u20131066.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"e_1_3_3_305_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-024-01974-2","article-title":"Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: A phase Ib\/II trial","volume":"9","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Huang Y, Yang Y, Zhao Y, Zhou T, Chen G, Zhao S, Zhou H, Ma Y, Hong S, et al. Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: A phase Ib\/II trial. Signal Transduct Target Ther. 2024;9(1):255.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"e_1_3_3_306_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010694","article-title":"Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: The GOIRC-01-2019 CeLEBrATE study","volume":"13","author":"Lamberti G","year":"2025","unstructured":"Lamberti G, Rihawi K, Mazzoni F, Riccardi F, Follador A, Tiseo M, Frassoldati A, Colantonio I, Bonetti A, Genova C, et al. Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: The GOIRC-01-2019 CeLEBrATE study. J Immunother Cancer. 2025;13(5): Article e010694.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"e_1_3_3_307_2","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2001.19.8.2114","article-title":"Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593\u2014A phase III trial of the Eastern Cooperative Oncology Group","volume":"19","author":"Schiller JH","year":"2001","unstructured":"Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593\u2014A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(8):2114\u20132122.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_3_308_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cllc.2025.02.002","article-title":"The PESGA trial: A prospective, open-label, single-arm, phase II study to evaluate first line therapy for extensive-stage small cell lung cancer (ES-SCLC) patients, treated by induction carboplatin\/etoposide\/pembrolizumab followed by maintenance of pembrolizumab\/sacituzumab govitecan","volume":"26","author":"Roisman LC","year":"2025","unstructured":"Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N. The PESGA trial: A prospective, open-label, single-arm, phase II study to evaluate first line therapy for extensive-stage small cell lung cancer (ES-SCLC) patients, treated by induction carboplatin\/etoposide\/pembrolizumab followed by maintenance of pembrolizumab\/sacituzumab govitecan. Clin Lung Cancer. 2025;26(4):267\u2013270.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"e_1_3_3_309_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41392-025-02153-7","article-title":"Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial","volume":"10","author":"Liu M","year":"2025","unstructured":"Liu M, Qiu G, Guan W, Xie X, Lin X, Xie Z, Zhang J, Qin Y, Du H, Chen X, et al. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial. Signal Transduct Target Ther. 2025;10(1):65.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_310_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116138","article-title":"Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15\/19)","volume":"232","author":"Addeo A","year":"2025","unstructured":"Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, Imbimbo M, K\u00f6nig D, Fernandez E, Patzen A, et al. Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15\/19). Eur J Cancer. 2025;232: Article 116138.","journal-title":"Eur J Cancer"},{"issue":"10","key":"e_1_3_3_311_2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson KG","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn M-J, Moskovitz M, Pogorzelski M, H\u00e4fliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025;26(10):1300\u20131311.","journal-title":"Lancet Oncol"},{"issue":"10495","key":"e_1_3_3_312_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares L","year":"2025","unstructured":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, \u015eendur MAN, Czy\u017cewicz G, Caro RB, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial. Lancet. 2025;405(10495):2129\u20132143.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_3_313_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jtho.2018.09.027","article-title":"Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial","volume":"14","author":"Christodoulou M","year":"2019","unstructured":"Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farr\u00e9 N, Zwitter M, Lerouge D, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2019;14(1):63\u201371.","journal-title":"J Thorac Oncol"},{"issue":"36","key":"e_1_3_3_314_2","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.2015.62.4270","article-title":"Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer","volume":"33","author":"Corso CD","year":"2015","unstructured":"Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. J Clin Oncol. 2015;33(36):4240\u20134246.","journal-title":"J Clin Oncol"},{"issue":"2","key":"e_1_3_3_315_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.21037\/tlcr.2016.03.03","article-title":"Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: That\u2019s the question","volume":"5","author":"Gridelli C","year":"2016","unstructured":"Gridelli C, Casaluce F, Sgambato A, Monaco F, Guida C. Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: That\u2019s the question. Transl Lung Cancer Res. 2016;5(2):150\u2013154.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"e_1_3_3_316_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4143\/crt.2023.931","article-title":"Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy","volume":"56","author":"Kim D","year":"2024","unstructured":"Kim D, Kim HJ, Wu H-G, Lee JH, Kim S, Kim TM, Kim J-S, Kim BH. Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy. Cancer Res Treat. 2024;56(2):430\u2013441.","journal-title":"Cancer Res Treat"},{"key":"e_1_3_3_317_2","article-title":"Consolidative thoracic radiotherapy with atezolizumab maintenance in extensive-stage small cell lung cancer: The phase 2 TREASURE randomized clinical trial (AIO-TRK-0320)","author":"Bozorgmehr F","year":"2026","unstructured":"Bozorgmehr F, Chung I, Behnisch R, Weykamp F, Adeberg S, Overbeck T, Shafie R, Maguire N, Koerber SA, Buchmeier EL, et al. Consolidative thoracic radiotherapy with atezolizumab maintenance in extensive-stage small cell lung cancer: The phase 2 TREASURE randomized clinical trial (AIO-TRK-0320). JAMA Oncol. 2026; Article e262330.","journal-title":"JAMA Oncol"},{"issue":"2","key":"e_1_3_3_318_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.7150\/jca.21465","article-title":"Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis","volume":"9","author":"Yang Y","year":"2018","unstructured":"Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, Cheng L, Chen Y, Du X, Qiu G. Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis. J Cancer. 2018;9(2):433\u2013439.","journal-title":"J Cancer"},{"issue":"7","key":"e_1_3_3_319_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman B","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664\u2013672.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_3_320_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2025.06.3884","article-title":"\u201cHope\u201d drives quality of life in patients with brain metastases, but, the \u201chope center\u201d remains elusive: An analysis of NRG-CC003","volume":"123","author":"Corn BW","year":"2025","unstructured":"Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH, et al. \u201cHope\u201d drives quality of life in patients with brain metastases, but, the \u201chope center\u201d remains elusive: An analysis of NRG-CC003. Int J Radiat Oncol Biol Phys. 2025;123(3):642\u2013652.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_3_321_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00221"},{"key":"e_1_3_3_322_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02767"},{"issue":"5","key":"e_1_3_3_323_2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jtho.2020.12.024","article-title":"Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)","volume":"16","author":"Belderbos JSA","year":"2021","unstructured":"Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, Dieleman EMT, Jaspers JPM, Van Meerbeeck JP, Ubbels F, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol. 2021;16(5):840\u2013849.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_324_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102871","article-title":"Brain metastasis burden and management in patients with small cell lung cancer in Canada: A retrospective, population-based cohort study","volume":"77","author":"Gaebe K","year":"2024","unstructured":"Gaebe K, Erickson AW, Chen S, Menjak IB, Lok BH, Sahgal A, Chan KKW, Das S. Brain metastasis burden and management in patients with small cell lung cancer in Canada: A retrospective, population-based cohort study. EClinicalMedicine. 2024;77: Article 102871.","journal-title":"EClinicalMedicine"},{"issue":"22","key":"e_1_3_3_325_2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO-25-02536","article-title":"Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for extensive-stage small cell lung cancer with brain-only progression after first-line treatment","volume":"44","author":"Lu S","year":"2026","unstructured":"Lu S, Jia J, Ren K, Jia W, Sun Z, Zhao K, Cai X, Zhao L, Zhu H. Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for extensive-stage small cell lung cancer with brain-only progression after first-line treatment. J Clin Oncol. 2026;44(22):2087\u20132097.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_326_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2025.06.3872","article-title":"Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: 3-year follow-up of a multicenter, single-arm, phase 2 trial (MATCH)","volume":"124","author":"Zhou L","year":"2025","unstructured":"Zhou L, Sun J, Xie C, Kang K, Yao Z, Gong Y, Huang M, Wang H, Wu L, Yuan Z, et al. Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: 3-year follow-up of a multicenter, single-arm, phase 2 trial (MATCH). Int J Radiat Oncol Biol Phys. 2025;124(1):164\u2013173.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"e_1_3_3_327_2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10555-024-10207-5","article-title":"Lost at SCLC: A review of potential platinum sensitizers","volume":"43","author":"Oronsky B","year":"2024","unstructured":"Oronsky B, Abrouk N, Mao L, Shen Y, Wang X, Zhao L, Caroen S, Reid T. Lost at SCLC: A review of potential platinum sensitizers. Cancer Metastasis Rev. 2024;43(4):1573\u20131578.","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"e_1_3_3_328_2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti AKP","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, D\u2019Avella C, Dowlati A, Downey RJ, Edelman M, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2021;19(12):1441\u20131464.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"9","key":"e_1_3_3_329_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize N","year":"2020","unstructured":"Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac J-B, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1224\u20131233.","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_330_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00992-5"},{"issue":"29","key":"e_1_3_3_331_2","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati A","year":"2024","unstructured":"Dowlati A, Hummel H-D, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, et al. Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update. J Clin Oncol. 2024;42(29):3392\u20133399.","journal-title":"J Clin Oncol"},{"issue":"22","key":"e_1_3_3_332_2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn M-J","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee J-S, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u20132075.","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_3_3_333_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios G","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M, Lugini A, Zhu B, Yu Y, Korantzis I, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393(4):349\u2013361.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_3_334_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie M","year":"2024","unstructured":"Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O\u2019Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study. Mol Cancer. 2024;23(1):115.","journal-title":"Mol Cancer"},{"issue":"5","key":"e_1_3_3_335_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo J","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, Peters S, Ponce S, Fern\u00e1ndez C, Alfaro V, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645\u2013654.","journal-title":"Lancet Oncol"},{"issue":"7","key":"e_1_3_3_336_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: The phase I\/II LUPER study","volume":"20","author":"Calles A","year":"2025","unstructured":"Calles A, Navarro A, de Speville Uribe BG, Colom\u00e9 E\u00c1, de Miguel M, \u00c1lvarez R, Arregui M, Moreno V, Rocha P, Calvo E, et al. Lurbinectedin plus pembrolizumab in relapsed SCLC: The phase I\/II LUPER study. J Thorac Oncol. 2025;20(7):969\u2013982.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_337_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix SP","year":"2023","unstructured":"Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Groh\u00e9 C, et al. Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023;11(1):74\u201386.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"e_1_3_3_338_2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"Pawel J","year":"1999","unstructured":"von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658\u2013667.","journal-title":"J Clin Oncol"},{"issue":"34","key":"e_1_3_3_339_2","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien MER","year":"2006","unstructured":"O\u2019Brien MER, Ciuleanu T-E, Tsekov H, Shparyk Y, \u010cu\u010devi\u00e1 B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441\u20135447.","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_3_3_340_2","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt JR","year":"2007","unstructured":"Eckardt JR, von Pawel J, Pujol J-L, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086\u20132092.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_341_2","first-page":"777","article-title":"Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer","volume":"26","author":"Yamamoto N","year":"2006","unstructured":"Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26(1B):777\u2013781.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_342_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7672"},{"key":"e_1_3_3_343_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman MJ","year":"2022","unstructured":"Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, et al. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer. 2022;166:135\u2013142.","journal-title":"Lung Cancer"},{"issue":"3","key":"e_1_3_3_344_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready NE","year":"2020","unstructured":"Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15(3):426\u2013435.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_345_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5069"},{"issue":"4","key":"e_1_3_3_346_2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung HC","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord J-P, Gao B, Planchard D, Gottfried M, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618\u2013627.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"e_1_3_3_347_2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451","volume":"39","author":"Owonikoko TK","year":"2021","unstructured":"Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodr\u00edguez-Cid J, Schenker M, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39(12):1349\u20131359.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_3_348_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606","volume":"32","author":"Spigel DR","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606. Ann Oncol. 2021;32(5):631\u2013641.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_349_2","unstructured":"Withdrawn | Cancer Accelerated Approvals. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals."},{"issue":"2","key":"e_1_3_3_350_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001302","article-title":"Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study","volume":"8","author":"Pakkala S","year":"2020","unstructured":"Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, et al. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study. J Immunother Cancer. 2020;8(2): Article e001302.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_351_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.003"},{"issue":"7","key":"e_1_3_3_352_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia SJ","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, J\u00e4ger D, Pietanza MC, Le DT, de Braud F, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(7):883\u2013895.","journal-title":"Lancet Oncol"},{"issue":"3","key":"e_1_3_3_353_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study","volume":"125","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 2021;125(3):366\u2013371.","journal-title":"Br J Cancer"},{"issue":"1","key":"e_1_3_3_354_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-024-01957-3","article-title":"Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: A phase II clinical trial","volume":"9","author":"Han X","year":"2024","unstructured":"Han X, Guo J, Li L, Huang Y, Meng X, Wang L, Zhu H, Meng X, Shao Q, Li X, et al. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: A phase II clinical trial. Signal Transduct Target Ther. 2024;9(1):241.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"e_1_3_3_355_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03","volume":"20","author":"Dowlati A","year":"2025","unstructured":"Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, Tazbirkova A, Sullivan IG, van Marcke C, Italiano A, et al. Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03. J Thorac Oncol. 2025;20(6):799\u2013808.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_356_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12916-026-04835-7","article-title":"Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: A phase II randomized controlled trial","volume":"24","author":"Guan M","year":"2026","unstructured":"Guan M, Zhao W, Zhang W, Chen X, Huang R, Liu X, Li Y, Wang H, Zhao L, Xu K, et al. Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: A phase II randomized controlled trial. BMC Med. 2026;24(1):383.","journal-title":"BMC Med"},{"issue":"7","key":"e_1_3_3_357_2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall survival and quality-of-life superiority in modern phase 3 oncology trials: A meta-epidemiological analysis","volume":"11","author":"Sherry AD","year":"2025","unstructured":"Sherry AD, Miller AM, Parlapalli JP, Kupferman GS, Beck EJ, McDonald J, Kouzy R, Abi Jaoude J, Lin TA, Sanford NN, et al. Overall survival and quality-of-life superiority in modern phase 3 oncology trials: A meta-epidemiological analysis. JAMA Oncol. 2025;11(7):718\u2013724.","journal-title":"JAMA Oncol"},{"key":"e_1_3_3_358_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107418","article-title":"Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide","volume":"186","author":"Liu SV","year":"2023","unstructured":"Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, et al. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023;186: Article 107418.","journal-title":"Lung Cancer"},{"issue":"1","key":"e_1_3_3_359_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13073-026-01624-y","article-title":"Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities","volume":"18","author":"Nones K","year":"2026","unstructured":"Nones K, Lakis V, Dalley AJ, Ryan K, Chittoory H, Ferguson K, Fitzgerald K, Newell F, Koufariotis LT, Bashirzadeh F, et al. Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities. Genome Med. 2026;18(1):47.","journal-title":"Genome Med"},{"key":"e_1_3_3_360_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217872","article-title":"AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study","volume":"628","author":"Khorrami M","year":"2025","unstructured":"Khorrami M, Mutha P, Barrera C, Viswanathan VS, Ardeshir-Larijani F, Jain P, Higgins K, Madabhushi A. AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study. Cancer Lett. 2025;628: Article 217872.","journal-title":"Cancer Lett"},{"issue":"8","key":"e_1_3_3_361_2","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1007\/s00259-026-07812-7","article-title":"Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial","volume":"53","author":"Datta A","year":"2026","unstructured":"Datta A, Spiller W, Mistry H, Julyan P, O\u2019Connor JP, Salem A, Faivre-Finn C, Manoharan P. Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial. Eur J Nucl Med Mol Imaging. 2026;53(8):4944\u20134954.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_3_3_362_2","doi-asserted-by":"crossref","DOI":"10.1177\/10732748261419190","article-title":"Interpretable machine learning for survival prediction in small cell lung cancer patients with brain metastases: A population-based study with external validation","volume":"33","author":"Luo N","year":"2026","unstructured":"Luo N, Tan S, Li X, Liu S, Xie S, Huang X, Wu D. Interpretable machine learning for survival prediction in small cell lung cancer patients with brain metastases: A population-based study with external validation. Cancer Control. 2026;33: Article 10732748261419190.","journal-title":"Cancer Control"},{"issue":"4","key":"e_1_3_3_363_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2026.102713","article-title":"Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer","volume":"7","author":"Zhang Z","year":"2026","unstructured":"Zhang Z, Wu D, Chen R, Zhai M, Yang F, Wang J, Guo L, Liu L, Ying J, Yang L, et al. Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Rep Med. 2026;7(4): Article 102713.","journal-title":"Cell Rep Med"},{"key":"e_1_3_3_364_2","article-title":"Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC","author":"Yang L","year":"2026","unstructured":"Yang L, Sheng R, Yang Z, Zhang Y, Wang T, Yang F, Liu S, Zhou M. Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC. npj Digit Med. 2026.","journal-title":"npj Digit Med"},{"issue":"5","key":"e_1_3_3_365_2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/2159-8290.CD-25-0099","article-title":"MANIFEST: Multiomic platform for cancer immunotherapy","volume":"15","author":"Lim KHJ","year":"2025","unstructured":"Lim KHJ, Tippu Z, Corrie PG, Hubank M, Larkin J, Lawley TD, Stares M, Stewart GD, Strange A, Symeonides SN, et al. MANIFEST: Multiomic platform for cancer immunotherapy. Cancer Discov. 2025;15(5):878\u2013883.","journal-title":"Cancer Discov"},{"issue":"5","key":"e_1_3_3_366_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ccell.2025.03.029","article-title":"AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes","volume":"43","author":"Arango-Argoty G","year":"2025","unstructured":"Arango-Argoty G, Bikiel DE, Sun GJ, Kipkogei E, Smith KM, Carrasco Pro S, Choe EY, Jacob E. AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes. Cancer Cell. 2025;43(5):875\u2013890.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_367_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.027"},{"key":"e_1_3_3_368_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1704"},{"issue":"1","key":"e_1_3_3_369_2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-025-02252-5","article-title":"Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: An exploratory biomarker analysis of a phase II study","volume":"10","author":"Xie M","year":"2025","unstructured":"Xie M, Bao M, Dong X, Wu L, Liu L, Zhao J, Chu X, Wu Y, Ji X, Fang Y, et al. Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: An exploratory biomarker analysis of a phase II study. Signal Transduct Target Ther. 2025;10(1):168.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"e_1_3_3_370_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-014840","article-title":"Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy","volume":"14","author":"Redavid AR","year":"2026","unstructured":"Redavid AR, Cifaldi L, Bei R, De Billy E, Fruci D. Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy. J Immunother Cancer. 2026;14(6): Article e014840.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_371_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.04.001"},{"issue":"1","key":"e_1_3_3_372_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson G","year":"2019","unstructured":"Manson G, Maria ATJ, Poizeau F, Danlos F-X, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, et al. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. J Immunother Cancer. 2019;7(1):337.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_373_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109418","article-title":"Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples","volume":"216","author":"Murata S","year":"2026","unstructured":"Murata S, Kashima J, Horinouchi H, Kishikawa S, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, et al. Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples. Lung Cancer. 2026;216: Article 109418.","journal-title":"Lung Cancer"},{"issue":"49","key":"e_1_3_3_374_2","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1038\/s41388-021-02044-5","article-title":"Correction: FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis","volume":"40","author":"Liang S-K","year":"2021","unstructured":"Liang S-K, Hsu C-C, Song H-L, Huang Y-C, Kuo C-W, Yao X, Li C-C, Yang H-C, Hung Y-L, Chao S-Y, et al. Correction: FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis. Oncogene. 2021;40(49):6705.","journal-title":"Oncogene"},{"issue":"7","key":"e_1_3_3_375_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41588-025-02233-y","article-title":"Predicting resistance to chemotherapy using chromosomal instability signatures","volume":"57","author":"Thompson JS","year":"2025","unstructured":"Thompson JS, Madrid L, Hernando B, Sauer CM, Vias M, Escobar-Rey M, Leung W-K, Garcia-Lopez D, Huckstep J, Sekowska M, et al. Predicting resistance to chemotherapy using chromosomal instability signatures. Nat Genet. 2025;57(7):1708\u20131717.","journal-title":"Nat Genet"},{"key":"e_1_3_3_376_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.09.002"},{"issue":"6","key":"e_1_3_3_377_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100631","article-title":"Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer","volume":"7","author":"Lang C","year":"2022","unstructured":"Lang C, Lantos A, Megyesfalvi Z, Egger F, Hoda MA, Mosleh B, Klikovits T, Oberndorfer F, Timelthaler G, Ferencz B, et al. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. ESMO Open. 2022;7(6): Article 100631.","journal-title":"ESMO Open"},{"key":"e_1_3_3_378_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1483"},{"issue":"1","key":"e_1_3_3_379_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41392-025-02445-y","article-title":"Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients","volume":"10","author":"Yang Y","year":"2025","unstructured":"Yang Y, Wu Y, Zhao J, Zhang T, Fei K, Zhao X, Deng L, Zhang Z, Jiang Y, Wang J, et al. Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. Signal Transduct Target Ther. 2025;10(1):347.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_3_380_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12964-025-02462-y","article-title":"Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction","volume":"23","author":"Fu Y","year":"2025","unstructured":"Fu Y, Zhou J, Chen X, Ding N, Zhao X, Bao H, Yang Y, Xia N. Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction. Cell Commun Signal. 2025;23(1):480.","journal-title":"Cell Commun Signal"},{"key":"e_1_3_3_381_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108723","article-title":"Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer","volume":"207","author":"Kurosaki T","year":"2025","unstructured":"Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, Tanizaki J, Suzuki S, Tomida S, Sakai K, et al. Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer. Lung Cancer. 2025;207: Article 108723.","journal-title":"Lung Cancer"},{"issue":"1","key":"e_1_3_3_382_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12967-026-08109-x","article-title":"Profiling the tumor-resident microbiota in small cell lung cancer and its influence on clinical outcomes","volume":"24","author":"Zhang W","year":"2026","unstructured":"Zhang W, Zhao W, Ye L, Wang H, Chen Z, Liu X, Li Y, Zhang Q, Zhang H, Liu Y, et al. Profiling the tumor-resident microbiota in small cell lung cancer and its influence on clinical outcomes. J Transl Med. 2026;24(1):537.","journal-title":"J Transl Med"},{"issue":"11","key":"e_1_3_3_383_2","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1158\/1078-0432.CCR-25-3302","article-title":"Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer","volume":"32","author":"Wu X","year":"2026","unstructured":"Wu X, Sun K, Zhang J, Hou S, Yuan Z, Ju Y, Deng J, Zhao J, Jin Y, She J, et al. Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer. Clin Cancer Res. 2026;32(11):2214\u20132229.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"e_1_3_3_384_2","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-24-2772","article-title":"Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy","volume":"85","author":"Redin E","year":"2025","unstructured":"Redin E, Otegui N, Santos M, Leon S, Redrado M, Serrano D, Fernandez de Pierola E, Russo-Cabrera JS, Ferrer I, Olmedo M, et al. Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy. Cancer Res. 2025;85(20):3910\u20133929.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_3_385_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-025-02383-x","article-title":"IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1\/-L1 therapy in SCLC","volume":"24","author":"Cui Y","year":"2025","unstructured":"Cui Y, Qiu T, Wang J, Liu X, Luo L, Yin J, Zhi X, Wang W, Feng G, Wu C, et al. IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1\/-L1 therapy in SCLC. Mol Cancer. 2025;24(1):187.","journal-title":"Mol Cancer"},{"issue":"5","key":"e_1_3_3_386_2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-020-01202-y","article-title":"The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response","volume":"124","author":"Coleman N","year":"2021","unstructured":"Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer. 2021;124(5):857\u2013859.","journal-title":"Br J Cancer"},{"key":"e_1_3_3_387_2","article-title":"PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials","volume":"42","author":"Pratama S","year":"2024","unstructured":"Pratama S, Wiyono L, Setiawan MS, Lauren BC. PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials. Cancer Treat Res Commun. 2024;42: Article 100874.","journal-title":"Cancer Treat Res Commun"},{"issue":"21","key":"e_1_3_3_388_2","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin CM","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC-H, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u20132379.","journal-title":"J Clin Oncol"},{"issue":"2","key":"e_1_3_3_389_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares L","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, Garassino MC, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2): Article 100408.","journal-title":"ESMO Open"},{"issue":"16","key":"e_1_3_3_390_2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","article-title":"Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial","volume":"29","author":"Spigel DR","year":"2011","unstructured":"Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial. J Clin Oncol. 2011;29(16):2215\u20132222.","journal-title":"J Clin Oncol"},{"issue":"35","key":"e_1_3_3_391_2","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","article-title":"Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501","volume":"27","author":"Horn L","year":"2009","unstructured":"Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009;27(35):6006\u20136011.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_3_392_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdv065","article-title":"Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial\u2020","volume":"26","author":"Pujol JL","year":"2015","unstructured":"Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial\u2020. Ann Oncol. 2015;26(5):908\u2013914.","journal-title":"Ann Oncol"},{"issue":"3","key":"e_1_3_3_393_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929","volume":"20","author":"Karim NA","year":"2025","unstructured":"Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao Y-Q, Redman MW, Carrizosa DR, Wang W-L, Petty WJ, et al. Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929. J Thorac Oncol. 2025;20(3):383\u2013394.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"e_1_3_3_394_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study","volume":"37","author":"Pistilli B","year":"2026","unstructured":"Pistilli B, Jhaveri K, Im S-A, Pernas S, De Laurentiis M, Wang S, Mart\u00ednez Ja\u00f1ez N, Borges G, Cescon DW, Hattori M, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol. 2026;37(5):663\u2013674.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_395_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0827"},{"key":"e_1_3_3_396_2","unstructured":"Multiple Endpoints in Clinical Trials. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials."},{"issue":"8","key":"e_1_3_3_397_2","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S1470-2045(24)00134-7","article-title":"Dose selection of novel anticancer drugs: Exposing the gap between selected and required doses","volume":"25","author":"Op\u2018t Hoog CJ","year":"2024","unstructured":"Op\u2018t Hoog CJ, Mehra N, Maliepaard M, Bol K, Gelderblom H, Sonke GS, de Langen AJ, van de Donk NW, Janssen JJ, Minnema MC, et al. Dose selection of novel anticancer drugs: Exposing the gap between selected and required doses. Lancet Oncol. 2024;25(8):e340\u2013e351.","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_398_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009"},{"key":"e_1_3_3_399_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.012"},{"issue":"3","key":"e_1_3_3_400_2","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473590","article-title":"Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials","volume":"45","author":"Azenkot T","year":"2025","unstructured":"Azenkot T, Rivera DR, Stewart MD, Patel SP. Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials. Am Soc Clin Oncol Educ Book. 2025;45(3): Article e473590.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_3_401_2","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128308066240529121148"},{"issue":"1","key":"e_1_3_3_402_2","first-page":"27","article-title":"Inductive transfer learning for molecular activity prediction: Next-gen QSAR models with MolPMoFiT","volume":"12","author":"Li X","year":"2020","unstructured":"Li X, Fourches D. Inductive transfer learning for molecular activity prediction: Next-gen QSAR models with MolPMoFiT. J Chem. 2020;12(1):27.","journal-title":"J Chem"},{"issue":"18","key":"e_1_3_3_403_2","doi-asserted-by":"crossref","first-page":"20338","DOI":"10.1021\/acsomega.4c00820","article-title":"Discovery of novel aldose reductase inhibitors via the integration of ligand-based and structure-based virtual screening with experimental validation","volume":"9","author":"Yasir M","year":"2024","unstructured":"Yasir M, Park J, Chun W. Discovery of novel aldose reductase inhibitors via the integration of ligand-based and structure-based virtual screening with experimental validation. ACS Omega. 2024;9(18):20338\u201320349.","journal-title":"ACS Omega"},{"key":"e_1_3_3_404_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5c00461"},{"key":"e_1_3_3_405_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.108734","article-title":"Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review","volume":"179","author":"Gangwal A","year":"2024","unstructured":"Gangwal A, Ansari A, Ahmad I, Azad AK, Wan Sulaiman WMA. Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review. Comput Biol Med. 2024;179: Article 108734.","journal-title":"Comput Biol Med"},{"issue":"1","key":"e_1_3_3_406_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-024-45461-2","article-title":"DynamicBind: Predicting ligand-specific protein-ligand complex structure with a deep equivariant generative model","volume":"15","author":"Lu W","year":"2024","unstructured":"Lu W, Zhang J, Huang W, Zhang Z, Jia X, Wang Z, Shi L, Li C, Wolynes PG, Zheng S. DynamicBind: Predicting ligand-specific protein-ligand complex structure with a deep equivariant generative model. Nat Commun. 2024;15(1):1071.","journal-title":"Nat Commun"},{"key":"e_1_3_3_407_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2"},{"key":"e_1_3_3_408_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8754"},{"key":"e_1_3_3_409_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07487-w"},{"issue":"1","key":"e_1_3_3_410_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-025-67361-9","article-title":"De novo design of epitope-specific antibodies via a structure-driven computational workflow","volume":"17","author":"Wu F","year":"2025","unstructured":"Wu F, Zhao Y, Wu J, Jiang B, He B, Huang L, Qin C, Xiao Y, Yang F, Wang R, et al. De novo design of epitope-specific antibodies via a structure-driven computational workflow. Nat Commun. 2025;17(1):625.","journal-title":"Nat Commun"},{"issue":"4","key":"e_1_3_3_411_2","article-title":"AttABseq: An attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences. Briefings in","volume":"25","author":"Jin R","year":"2024","unstructured":"Jin R, Ye Q, Wang J, Cao Z, Jiang D, Wang T, Kang Y, Xu W, Hsieh C-Y, Hou T. AttABseq: An attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences. Briefings in. Bioinformatics. 2024;25(4): Article bbae304.","journal-title":"Bioinformatics"},{"key":"e_1_3_3_412_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06415-8"},{"issue":"1","key":"e_1_3_3_413_2","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2528902","article-title":"Artificial intelligence-driven computational methods for antibody design and optimization","volume":"17","author":"Vecchietti LF","year":"2025","unstructured":"Vecchietti LF, Wijaya BN, Armanuly A, Hangeldiyev B, Jung H, Lee S, Cha M, Kim HM. Artificial intelligence-driven computational methods for antibody design and optimization. MAbs. 2025;17(1): Article 2528902.","journal-title":"MAbs"},{"key":"e_1_3_3_414_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.3c01753"},{"key":"e_1_3_3_415_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612829666230428110542"},{"issue":"1","key":"e_1_3_3_416_2","first-page":"144","article-title":"Evaluating ligand docking methods for drugging protein-protein interfaces: Insights from AlphaFold2 and molecular dynamics refinement","volume":"17","author":"G\u00f3mez Borrego J","year":"2025","unstructured":"G\u00f3mez Borrego J, Torrent Burgas M. Evaluating ligand docking methods for drugging protein-protein interfaces: Insights from AlphaFold2 and molecular dynamics refinement. J Chem. 2025;17(1):144.","journal-title":"J Chem"},{"key":"e_1_3_3_417_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.3c00519"},{"issue":"3","key":"e_1_3_3_418_2","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1021\/acs.jcim.5c02204","article-title":"A relative binding free energy framework for structurally dissimilar molecules","volume":"66","author":"Tsai H-C","year":"2026","unstructured":"Tsai H-C, Zhang S, Lee T-S, Giese TJ, Lin C, Xu J, Yi Y, York DM, Ganguly A, Pan AC. A relative binding free energy framework for structurally dissimilar molecules. J Chem Inf Model. 2026;66(3):1626\u20131636.","journal-title":"J Chem Inf Model"},{"issue":"5","key":"e_1_3_3_419_2","doi-asserted-by":"crossref","DOI":"10.1063\/5.0155600","article-title":"DeePMD-kit v2: A software package for deep potential models","volume":"159","author":"Zeng J","year":"2023","unstructured":"Zeng J, Zhang D, Lu D, Mo P, Li Z, Chen Y, Rynik M, La H, Li Z, Shi S, et al. DeePMD-kit v2: A software package for deep potential models. J Chem Phys. 2023;159(5): Article 054801.","journal-title":"J Chem Phys"},{"issue":"24","key":"e_1_3_3_420_2","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1021\/acs.jcim.5c02250","article-title":"ProfhEX: Empowering early drug discovery with machine learning-based target profiling and liability prediction","volume":"65","author":"Lunghini F","year":"2025","unstructured":"Lunghini F, Cerchia C, Fava A, Pisapia V, Sacco F, Beccari AR. ProfhEX: Empowering early drug discovery with machine learning-based target profiling and liability prediction. J Chem Inf Model. 2025;65(24):13037\u201313044.","journal-title":"J Chem Inf Model"},{"issue":"3","key":"e_1_3_3_421_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1039\/D1SC05180F","article-title":"MGraphDTA: Deep multiscale graph neural network for explainable drug-target binding affinity prediction","volume":"13","author":"Yang Z","year":"2022","unstructured":"Yang Z, Zhong W, Zhao L, Chen CY-C. MGraphDTA: Deep multiscale graph neural network for explainable drug-target binding affinity prediction. Chem Sci. 2022;13(3):816\u2013833.","journal-title":"Chem Sci"},{"issue":"1","key":"e_1_3_3_422_2","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1038\/s41467-025-59628-y","article-title":"Token-Mol 1.0: Tokenized drug design with large language models","volume":"16","author":"Wang J","year":"2025","unstructured":"Wang J, Qin R, Wang M, Fang M, Zhang Y, Zhu Y, Su Q, Gou Q, Shen C, Zhang O, et al. Token-Mol 1.0: Tokenized drug design with large language models. Nat Commun. 2025;16(1):4416.","journal-title":"Nat Commun"},{"issue":"3","key":"e_1_3_3_423_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.124.070413","article-title":"ADMET-AI enables interpretable predictions of drug-induced cardiotoxicity","volume":"151","author":"Mukherjee S","year":"2025","unstructured":"Mukherjee S, Swanson K, Walther P, Shivnaraine RV, Leitz J, Pang PD, Zou J, Wu JC. ADMET-AI enables interpretable predictions of drug-induced cardiotoxicity. Circulation. 2025;151(3):285\u2013287.","journal-title":"Circulation"},{"issue":"1","key":"e_1_3_3_424_2","doi-asserted-by":"crossref","first-page":"W469","DOI":"10.1093\/nar\/gkae254","article-title":"Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction","volume":"52","author":"Myung Y","year":"2024","unstructured":"Myung Y, de S\u00e1 AGC, Ascher DB. Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic Acids Res. 2024;52(W1):W469\u2013W475.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_3_425_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-022-01055-3"},{"key":"e_1_3_3_426_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08393-x"},{"issue":"1","key":"e_1_3_3_427_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/acs.molpharmaceut.4c00804","article-title":"Machine learning models for predicting monoclonal antibody biophysical properties from molecular dynamics simulations and deep learning-based surface descriptors","volume":"22","author":"Wu I-E","year":"2025","unstructured":"Wu I-E, Kalejaye L, Lai P-K. Machine learning models for predicting monoclonal antibody biophysical properties from molecular dynamics simulations and deep learning-based surface descriptors. Mol Pharm. 2025;22(1):142\u2013153.","journal-title":"Mol Pharm"},{"key":"e_1_3_3_428_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278"},{"key":"e_1_3_3_429_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1421"},{"key":"e_1_3_3_430_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108841","article-title":"NHWD-870 suppresses tumor proliferation via the BRD4\/STRADA\/CCND1 axis in small cell lung cancer","volume":"210","author":"Ma L","year":"2025","unstructured":"Ma L, Zhang X, Xu S, Dai J, Huang Z, Ruan Z, Zhang Y, Zhou X, Sun Y, Chen Y, et al. NHWD-870 suppresses tumor proliferation via the BRD4\/STRADA\/CCND1 axis in small cell lung cancer. Lung Cancer. 2025;210: Article 108841.","journal-title":"Lung Cancer"},{"issue":"8","key":"e_1_3_3_431_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1541-7786.MCR-23-0599","article-title":"MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor mivebresib (ABBV075) in small-cell lung cancer","volume":"22","author":"Plotnik JP","year":"2024","unstructured":"Plotnik JP, Zha Z, Feng W, Lee I, Riehm J, McClure RA, Sandoval S, Uziel T, Murphy E, Lu X, et al. MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor mivebresib (ABBV075) in small-cell lung cancer. Mol Cancer Res. 2024;22(8):689\u2013698.","journal-title":"Mol Cancer Res"},{"issue":"10","key":"e_1_3_3_432_2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/1535-7163.MCT-23-0065","article-title":"First-in-human study of AZD5153, A small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma","volume":"22","author":"Hamilton EP","year":"2023","unstructured":"Hamilton EP, Wang JS, Oza AM, Patel MR, Ulahannan SV, Bauer T, Karlix JL, Zeron-Medina J, Fabbri G, Marco-Casanova P, et al. First-in-human study of AZD5153, A small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma. Mol Cancer Ther. 2023;22(10):1154\u20131165.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_3_433_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-23-0405"},{"issue":"5","key":"e_1_3_3_434_2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156657","article-title":"mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer","volume":"8","author":"Kumari A","year":"2023","unstructured":"Kumari A, Gesumaria L, Liu Y-J, Hughitt VK, Zhang X, Ceribelli M, Wilson KM, Klumpp-Thomas C, Chen L, McKnight C, et al. mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. JCI Insight. 2023;8(5): Article e156657.","journal-title":"JCI Insight"},{"issue":"7","key":"e_1_3_3_435_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110814","article-title":"WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC","volume":"39","author":"Taniguchi H","year":"2022","unstructured":"Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39(7): Article 110814.","journal-title":"Cell Rep"},{"issue":"3","key":"e_1_3_3_436_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/cancers17030446","article-title":"Polo-like kinase 1 inhibitors demonstrate in\u00a0vitro and in\u00a0vivo efficacy in preclinical models of small cell lung cancer","volume":"17","author":"Zhang G","year":"2025","unstructured":"Zhang G, Pannucci A, Ivanov AA, Switchenko J, Sun S-Y, Sica GL, Liu Z, Huang Y, Schmitz JC, Owonikoko TK. Polo-like kinase 1 inhibitors demonstrate in\u00a0vitro and in\u00a0vivo efficacy in preclinical models of small cell lung cancer. Cancers. 2025;17(3):446.","journal-title":"Cancers"},{"key":"e_1_3_3_437_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0389"},{"issue":"5","key":"e_1_3_3_438_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.21037\/tlcr-24-33","article-title":"CDK4\/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer","volume":"13","author":"Wang L","year":"2024","unstructured":"Wang L, Wu Y, Kang K, Zhang X, Luo R, Tu Z, Zheng Y, Lin G, Wang H, Tang M, et al. CDK4\/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer. Transl Lung Cancer Res. 2024;13(5):1032\u20131046.","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_3_3_439_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.11.003"},{"issue":"8085","key":"e_1_3_3_440_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41586-025-09433-w","article-title":"Targeting G1-S-checkpoint-compromised cancers with cyclin A\/B RxL inhibitors","volume":"646","author":"Singh S","year":"2025","unstructured":"Singh S, Gleason CE, Fang M, Laimon YN, Khivansara V, Xie S, Durmaz YT, Sarkar A, Ngo K, Savla V, et al. Targeting G1-S-checkpoint-compromised cancers with cyclin A\/B RxL inhibitors. Nature. 2025;646(8085):734\u2013745.","journal-title":"Nature"},{"key":"e_1_3_3_441_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0602"},{"issue":"2","key":"e_1_3_3_442_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: Primary and correlative biomarker analyses","volume":"15","author":"Owonikoko TK","year":"2020","unstructured":"Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AA, Chouaid C, Jaime JC, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: Primary and correlative biomarker analyses. J Thorac Oncol. 2020;15(2):274\u2013287.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_443_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0375"},{"key":"e_1_3_3_444_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2964"},{"issue":"1","key":"e_1_3_3_445_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice","volume":"9","author":"Khan S","year":"2023","unstructured":"Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, et al. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 2023;9(1):1.","journal-title":"Cell Death Discov"},{"key":"e_1_3_3_446_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117375","article-title":"Comparative in\u00a0vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation","volume":"500","author":"Deppas JJ","year":"2025","unstructured":"Deppas JJ, Kiesel BF, Guo J, Rigatti LH, Latoche JD, Green A, Knizner P, Clump DA, Pandya P, Vendetti FP, et al. Comparative in\u00a0vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation. Toxicol Appl Pharmacol. 2025;500: Article 117375.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"e_1_3_3_447_2","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217313","article-title":"ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer","volume":"15","author":"Schultz CW","year":"2023","unstructured":"Schultz CW, Zhang Y, Elmeskini R, Zimmermann A, Fu H, Murai Y, Wangsa D, Kumar S, Takahashi N, Atkinson D, et al. ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer. EMBO Mol Med. 2023;15(8): Article e17313.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"e_1_3_3_448_2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jtho.2021.04.001","article-title":"Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: A randomized, double-blind, phase 3 study","volume":"16","author":"Ai X","year":"2021","unstructured":"Ai X, Pan Y, Shi J, Yang N, Liu C, Zhou J, Zhang X, Dong X, He J, Li X, et al. Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: A randomized, double-blind, phase 3 study. J Thorac Oncol. 2021;16(8):1403\u20131414.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_449_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-4342"},{"key":"e_1_3_3_450_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0486"},{"key":"e_1_3_3_451_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.014"},{"issue":"567","key":"e_1_3_3_452_2","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert A","year":"2019","unstructured":"Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton KD, Martins R, Poirier JT, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019;12(567): Article eaau2922.","journal-title":"Sci Signal"},{"key":"e_1_3_3_453_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.008"},{"issue":"1","key":"e_1_3_3_454_2","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/s41467-022-31998-7","article-title":"Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1","volume":"13","author":"Chen H-Y","year":"2022","unstructured":"Chen H-Y, Durmaz YT, Li Y, Sabet AH, Vajdi A, Denize T, Walton E, Laimon YN, Doench JG, Mahadevan NR, et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nat Commun. 2022;13(1):4998.","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_3_3_455_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-025-02552-y","article-title":"HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-\u03b2\/SMAD and CSF1R signaling","volume":"25","author":"Jiang Y","year":"2026","unstructured":"Jiang Y, Yu J, Wang T, Du Q, Wang J, Lu Y, Xu Q, Liu H, Li X, Tong L, et al. HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-\u03b2\/SMAD and CSF1R signaling. Mol Cancer. 2026;25(1):33.","journal-title":"Mol Cancer"},{"issue":"38","key":"e_1_3_3_456_2","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-024-03125-x","article-title":"Jumonji histone demethylases are therapeutic targets in small cell lung cancer","volume":"43","author":"Nguyen A","year":"2024","unstructured":"Nguyen A, Nu\u00f1ez CG, Tran TA, Girard L, Peyton M, Catalan R, Guerena C, Avila K, Drapkin BJ, Chandra R, et al. Jumonji histone demethylases are therapeutic targets in small cell lung cancer. Oncogene. 2024;43(38):2885\u20132899.","journal-title":"Oncogene"},{"issue":"1","key":"e_1_3_3_457_2","doi-asserted-by":"crossref","first-page":"7704","DOI":"10.1038\/s41467-026-73271-1","article-title":"TRIM21-mediated ubiquitination of PARP1 regulated by the PI3K\/AKT-STAT5A axis suppresses small cell lung cancer","volume":"17","author":"Cao G","year":"2026","unstructured":"Cao G, Li G, Wang X, Zhang T, Yao X, Hou P, Zhang J, Guo X, Wang J, Xiang L, et al. TRIM21-mediated ubiquitination of PARP1 regulated by the PI3K\/AKT-STAT5A axis suppresses small cell lung cancer. Nat Commun. 2026;17(1):7704.","journal-title":"Nat Commun"},{"key":"e_1_3_3_458_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"issue":"5","key":"e_1_3_3_459_2","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/j.cllc.2022.04.005","article-title":"Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer","volume":"23","author":"Rimner A","year":"2022","unstructured":"Rimner A, Lai W-CV, Califano R, Jabbour SK, Rudin CM, Faivre-Finn C, Cho BC, Kato T, Yu J, Chafin W, et al. Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer. Clin Lung Cancer. 2022;23(5):e325\u2013e329.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"e_1_3_3_460_2","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1038\/s41467-026-70984-1","article-title":"LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC","volume":"17","author":"Machida T","year":"2026","unstructured":"Machida T, Gong Y, Tsukioka S, Onodera A, Nakayama A, Hashimoto N, Fuchigami T, Nishimura M, Ogino T, Kurimoto R, et al. LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC. Nat Commun. 2026;17(1):4390.","journal-title":"Nat Commun"},{"issue":"11","key":"e_1_3_3_461_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101282","article-title":"Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1","volume":"4","author":"Li Y","year":"2023","unstructured":"Li Y, Mahadevan NR, Duplaquet L, Hong D, Durmaz YT, Jones KL, Cho H, Morrow M, Protti A, Poitras MJ, et al. Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. Cell Rep Med. 2023;4(11): Article 101282.","journal-title":"Cell Rep Med"},{"issue":"2","key":"e_1_3_3_462_2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.semcancer.2022.05.004","article-title":"Small cell lung cancer: Novel treatments beyond immunotherapy","volume":"86","author":"Meijer J-J","year":"2022","unstructured":"Meijer J-J, Leonetti A, Air\u00f2 G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M. Small cell lung cancer: Novel treatments beyond immunotherapy. Semin Cancer Biol. 2022;86(Pt 2):376\u2013385.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"e_1_3_3_463_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00262-024-03932-x","article-title":"Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: An open-label, single-arm, multicenter, multi-cohort phase II trial","volume":"74","author":"Cheng Y","year":"2025","unstructured":"Cheng Y, Zhang P, Lu M, Chen Z, Song L, Shi S, Ye F, Zhang X, Liu B, Ji D, et al. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: An open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunol Immunother. 2025;74(3):83.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"e_1_3_3_464_2","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1038\/s41467-026-73562-7","article-title":"Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): A multicenter, randomized, phase II trial and biomarker analysis","volume":"17","author":"Zhang B","year":"2026","unstructured":"Zhang B, Zhong R, Shi C, Chu T, Zhang W, Wang H, Gan X, Zhang Z, Zhu C, Li X, et al. Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): A multicenter, randomized, phase II trial and biomarker analysis. Nat Commun. 2026;17(1):6780.","journal-title":"Nat Commun"},{"key":"e_1_3_3_465_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00817-8"},{"issue":"7","key":"e_1_3_3_466_2","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1021\/acs.jmedchem.3c02332","article-title":"Beyond rule of five and PROTACs in modern drug discovery: Polarity reducers, chameleonicity, and the evolving physicochemical landscape","volume":"67","author":"Price E","year":"2024","unstructured":"Price E, Weinheimer M, Rivkin A, Jenkins G, Nijsen M, Cox PB, DeGoey D. Beyond rule of five and PROTACs in modern drug discovery: Polarity reducers, chameleonicity, and the evolving physicochemical landscape. J Med Chem. 2024;67(7):5683\u20135698.","journal-title":"J Med Chem"},{"issue":"6","key":"e_1_3_3_467_2","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag133","article-title":"Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-\u03b2 in patients with advanced solid tumors","volume":"31","author":"Sun H","year":"2026","unstructured":"Sun H, Chen G, Xue J, Zhang Y, Ma Y, Yang Y, Fang W, Zhao Y, Huang Y, Hong S, et al. Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-\u03b2 in patients with advanced solid tumors. Oncologist. 2026;31(6): Article oyag133.","journal-title":"Oncologist"},{"key":"e_1_3_3_468_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01262-w"},{"key":"e_1_3_3_469_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00833-z"},{"key":"e_1_3_3_470_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.06.001"},{"issue":"3","key":"e_1_3_3_471_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin CM","year":"2024","unstructured":"Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee J-S, Bryl M, Dumoulin DW, Rittmeyer A, Chiu C-H, et al. SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2024;42(3):324\u2013335.","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_3_472_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012729","article-title":"First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and\/or metastatic solid tumors","volume":"14","author":"Rohrberg KS","year":"2026","unstructured":"Rohrberg KS, Melero I, Sanmamed M, Mu\u00f1oz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, et al. First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and\/or metastatic solid tumors. J Immunother Cancer. 2026;14(6): Article e012729.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_473_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-25-1454"},{"key":"e_1_3_3_474_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00896-6"},{"issue":"12","key":"e_1_3_3_475_2","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41401-025-01584-w","article-title":"Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer","volume":"46","author":"Bo Q","year":"2025","unstructured":"Bo Q, Zhang M-G, Yang F, Zheng Y, Li Z-L, Zheng Y-M, Wu F-M, Liang J, Zhou L, Li D-S, et al. Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer. Acta Pharmacol Sin. 2025;46(12):3291\u20133301.","journal-title":"Acta Pharmacol Sin"},{"key":"e_1_3_3_476_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00905-y"},{"key":"e_1_3_3_477_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0638"},{"key":"e_1_3_3_478_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.09.001"},{"issue":"16","key":"e_1_3_3_479_2","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1158\/1078-0432.CCR-24-3981","article-title":"Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes","volume":"31","author":"Gay CM","year":"2025","unstructured":"Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, et al. Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes. Clin Cancer Res. 2025;31(16):3476\u20133482.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"e_1_3_3_480_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin CM","year":"2026","unstructured":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N, Rocha P, Hayashi H, Sakai T, Kim YJ, et al. Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial. J Clin Oncol. 2026;44(4):261\u2013273.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_3_481_2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","article-title":"HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a\/b trial","volume":"44","author":"Duan J","year":"2026","unstructured":"Duan J, Sun Y, Wang Q, Xing L, Wu L, Han L, Chen J, Liu B, Lu P, Shi H, et al. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a\/b trial. Cancer Cell. 2026;44(4):846\u2013857.","journal-title":"Cancer Cell"},{"issue":"22","key":"e_1_3_3_482_2","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1158\/1078-0432.CCR-24-1547","article-title":"A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer","volume":"30","author":"Morgensztern D","year":"2024","unstructured":"Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, et al. A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer. Clin Cancer Res. 2024;30(22):5042\u20135052.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_483_2","article-title":"Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a phase Ib study","author":"Zhao Y","year":"2026","unstructured":"Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, Yang W, He Z, Wang Y, Ma Y, et al. Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a phase Ib study. J Clin Oncol. 2026; Article JCO2600243.","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_3_484_2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","article-title":"Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: A potent and novel therapeutic for the treatment of small cell lung cancer","volume":"18","author":"Whalen KA","year":"2019","unstructured":"Whalen KA, White BH, Quinn JM, Kriksciukaite K, Alargova R, Au Yeung TP, Bazinet P, Brockman A, DuPont MM, Oller H, et al. Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: A potent and novel therapeutic for the treatment of small cell lung cancer. Mol Cancer Ther. 2019;18(11):1926\u20131936.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_3_485_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3"},{"key":"e_1_3_3_486_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2293"},{"key":"e_1_3_3_487_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2346"},{"key":"e_1_3_3_488_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.013"},{"key":"e_1_3_3_489_2","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/0008-5472.CAN-25-5261","article-title":"Parallel 4-1BB signaling in dual DLL3\/CD56-targeting CAR-T cells triggers adaptive proliferation and functional persistence to eradicate small cell lung cancer","author":"Lei Y-N","year":"2026","unstructured":"Lei Y-N, Qin D, He Y, Shu P, Zhang B, Chen Y, Liu N, He X, Zhang Y-G, Chang M-Y, et al. Parallel 4-1BB signaling in dual DLL3\/CD56-targeting CAR-T cells triggers adaptive proliferation and functional persistence to eradicate small cell lung cancer. Cancer Res. 2026;OF1\u2013OF17.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_3_490_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel L","year":"2022","unstructured":"Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fuc\u00e0 G, Weiss J, Dotti G, Pecot CV, Savoldo B. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 2022;10(1): Article e003897.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_491_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0259"},{"key":"e_1_3_3_492_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215697","article-title":"Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer","volume":"538","author":"Taromi S","year":"2022","unstructured":"Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M, Passlick B, Schumacher A, Lagies S, Frey A, et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022;538: Article 215697.","journal-title":"Cancer Lett"},{"issue":"1","key":"e_1_3_3_493_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-025-01729-8","article-title":"Targeting CD276 with adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide","volume":"18","author":"Kristmann B","year":"2025","unstructured":"Kristmann B, Werchau N, Suresh L, Pezzuto EL, Scheuermann S, Krost S, Schilbach K, Moustafa-Oglou M, Mast A-S, Droste M, et al. Targeting CD276 with adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide. J Hematol Oncol. 2025;18(1):76.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"e_1_3_3_494_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010073","article-title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","volume":"13","author":"Zhang H","year":"2025","unstructured":"Zhang H, Xia L, Xuzhang W, Li Z, Zhang J, Li F, Cheng C, Wang J, Zong X, Yang X, et al. BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer. J Immunother Cancer. 2025;13(5): Article e010073.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_3_3_495_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000785","article-title":"Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth","volume":"8","author":"Chen X","year":"2020","unstructured":"Chen X, Amar N, Zhu Y, Wang C, Xia C, Yang X, Wu D, Feng M. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. J Immunother Cancer. 2020;8(1): Article e000785.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_496_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.017"},{"issue":"26","key":"e_1_3_3_497_2","first-page":"00443-1","article-title":"Trained immunity-primed DLL3-targeted CAR macrophages for the eradication of small cell lung cancer","volume":"2090","author":"Ying H","year":"2026","unstructured":"Ying H, Wang Y, Li N, Ma W, Shou X, Liu Z, Chen C, Dong Z, Li H-W, Zhang J, et al. Trained immunity-primed DLL3-targeted CAR macrophages for the eradication of small cell lung cancer. J Adv Res. 2026;S2090-1232(26):00443-1.","journal-title":"J Adv Res"},{"issue":"1","key":"e_1_3_3_498_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar T","year":"2025","unstructured":"Dolkar T, Gates C, Hao Z, Munker R. New developments in immunotherapy for SCLC. J Immunother Cancer. 2025;13(1): Article e009667.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"e_1_3_3_499_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in\u00a0vitro and in\u00a0vivo","volume":"112","author":"Liu M","year":"2022","unstructured":"Liu M, Huang W, Guo Y, Zhou Y, Zhi C, Chen J, Li J, He J, Lian H, Zhou J, et al. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in\u00a0vitro and in\u00a0vivo. J Leukoc Biol. 2022;112(4):901\u2013911.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"e_1_3_3_500_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin D","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_501_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.010"},{"issue":"7","key":"e_1_3_3_502_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-015351","article-title":"Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Phase Ib-II VENEZOLUNG trial","volume":"14","author":"Gonzalez-Cao M","year":"2026","unstructured":"Gonzalez-Cao M, Sister\u00e9-Or\u00f3 M, Moran T, Reguart N, Cabezon R, Hern\u00e1ndez A, Roman R, Molina-Vila MA, Birgin K, Domenjo-Vila E, et al. Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Phase Ib-II VENEZOLUNG trial. J Immunother Cancer. 2026;14(7): Article e015351.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"e_1_3_3_503_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s12026-023-09404-1","article-title":"Translational and structural vaccinomics approach to design a multi-epitope vaccine against NOL4 autologous antigen of small cell lung cancer","volume":"71","author":"Rathi B","year":"2023","unstructured":"Rathi B, Santoshi S. Translational and structural vaccinomics approach to design a multi-epitope vaccine against NOL4 autologous antigen of small cell lung cancer. Immunol Res. 2023;71(6):909\u2013928.","journal-title":"Immunol Res"},{"issue":"7","key":"e_1_3_3_504_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/2159-8290.CD-25-0300","article-title":"The future of personalized cancer vaccines","volume":"15","author":"Martini DJ","year":"2025","unstructured":"Martini DJ, Wu CJ. The future of personalized cancer vaccines. Cancer Discov. 2025;15(7):1315\u20131324.","journal-title":"Cancer Discov"},{"issue":"6","key":"e_1_3_3_505_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156211","article-title":"Messenger RNA vaccines for cancer immunotherapy: Progress promotes promise","volume":"132","author":"Huff AL","year":"2022","unstructured":"Huff AL, Jaffee EM, Zaidi N. Messenger RNA vaccines for cancer immunotherapy: Progress promotes promise. J Clin Invest. 2022;132(6): Article e156211.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_506_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0"},{"key":"e_1_3_3_507_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01025-x"},{"issue":"19","key":"e_1_3_3_508_2","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1016\/j.cell.2025.08.025","article-title":"Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells","volume":"188","author":"Wang HH","year":"2025","unstructured":"Wang HH, Zaidi N. Multi-adjuvant personalized neoantigen vaccines: Fine-tuning anti-cancer T cells. Cell. 2025;188(19):5121\u20135123.","journal-title":"Cell"},{"key":"e_1_3_3_509_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.05.003"},{"key":"e_1_3_3_510_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adq1741"},{"issue":"8","key":"e_1_3_3_511_2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41589-025-01950-z","article-title":"Harnessing computational technologies to facilitate antibody-drug conjugate development","volume":"21","author":"Croitoru A","year":"2025","unstructured":"Croitoru A, Orr AA, MacKerell AD Jr. Harnessing computational technologies to facilitate antibody-drug conjugate development. Nat Chem Biol. 2025;21(8):1138\u20131147.","journal-title":"Nat Chem Biol"},{"issue":"8","key":"e_1_3_3_512_2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ccell.2025.06.008","article-title":"The dark side of radiotherapy","volume":"43","author":"Piffk\u00f3 A","year":"2025","unstructured":"Piffk\u00f3 A, Pitroda SP, Weichselbaum RR. The dark side of radiotherapy. Cancer Cell. 2025;43(8):1385\u20131389.","journal-title":"Cancer Cell"},{"key":"e_1_3_3_513_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.004"},{"key":"e_1_3_3_514_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.010"},{"key":"e_1_3_3_515_2","article-title":"SEZ6-targeted PET imaging and alpha-particle radioimmunotherapy is effective for detection and treatment of small cell lung cancer","author":"Ghaemi B","year":"2026","unstructured":"Ghaemi B, Olkowski CP, Basuli F, Shi J, Lang L, Thomas A, Choyke PL, Jacobson O. SEZ6-targeted PET imaging and alpha-particle radioimmunotherapy is effective for detection and treatment of small cell lung cancer. Cancer Res. 2026.","journal-title":"Cancer Res"},{"issue":"6","key":"e_1_3_3_516_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2505785123","article-title":"Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers","volume":"123","author":"Tendler S","year":"2026","unstructured":"Tendler S, De Gregorio R, Balderes P, Michel AL, Hoang TT, Bauer D, Tully KM, Korsen JA, Lorenz IC, Khan AG, et al. Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers. Proc Natl Acad Sci USA. 2026;123(6): Article e2505785123.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"e_1_3_3_517_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102549","article-title":"c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors","volume":"7","author":"Balke-Want H","year":"2026","unstructured":"Balke-Want H, Keerthi V, Del Carmen AM, Chen Y, Malipatlolla M, Klysz DD, Xu P, Ho K, Asano K, Stahl D, et al. c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. Cell Rep Med. 2026;7(1): Article 102549.","journal-title":"Cell Rep Med"},{"issue":"1","key":"e_1_3_3_518_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114348","article-title":"Enhancing cisplatin therapy for small cell lung cancer via a dual strategy of combining surufatinib and CD47 blockade","volume":"388","author":"Li K","year":"2025","unstructured":"Li K, Lin Z, Wu T, Zhou J, Wu J, Zhou Y, Gao H, Lin Y, Chen X, Xu H, et al. Enhancing cisplatin therapy for small cell lung cancer via a dual strategy of combining surufatinib and CD47 blockade. J Control Release. 2025;388(Pt 1): Article 114348.","journal-title":"J Control Release"},{"issue":"6","key":"e_1_3_3_519_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney SM","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med. 2026;394(6):551\u2013562.","journal-title":"N Engl J Med"},{"issue":"13","key":"e_1_3_3_520_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMsr2214184","article-title":"Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine","volume":"388","author":"Lee P","year":"2023","unstructured":"Lee P, Bubeck S, Petro J. Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine. N Engl J Med. 2023;388(13):1233\u20131239.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_3_521_2","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1038\/s41467-025-64105-7","article-title":"Evaluating large language model agents for automation of atomic force microscopy","volume":"16","author":"Mandal I","year":"2025","unstructured":"Mandal I, Soni J, Zaki M, Smedskjaer MM, Wondraczek K, Wondraczek L, Gosvami NN, Krishnan NMA. Evaluating large language model agents for automation of atomic force microscopy. Nat Commun. 2025;16(1):9104.","journal-title":"Nat Commun"},{"key":"e_1_3_3_522_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29122716"},{"issue":"3","key":"e_1_3_3_523_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2024.10346","article-title":"Using a virtual scribe may shorten EHR time","volume":"332","author":"Bock A","year":"2024","unstructured":"Bock A. Using a virtual scribe may shorten EHR time. JAMA. 2024;332(3):188.","journal-title":"JAMA"},{"key":"e_1_3_3_524_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2503956"},{"issue":"1","key":"e_1_3_3_525_2","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1038\/s41467-024-53081-z","article-title":"Matching patients to clinical trials with large language models","volume":"15","author":"Jin Q","year":"2024","unstructured":"Jin Q, Wang Z, Floudas CS, Chen F, Gong C, Bracken-Clarke D, Xue E, Yang Y, Sun J, Lu Z. Matching patients to clinical trials with large language models. Nat Commun. 2024;15(1):9074.","journal-title":"Nat Commun"},{"issue":"4","key":"e_1_3_3_526_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41551-025-01363-2","article-title":"Coordinated AI agents for advancing healthcare","volume":"9","author":"Moritz M","year":"2025","unstructured":"Moritz M, Topol E, Rajpurkar P. Coordinated AI agents for advancing healthcare. Nat Biomed Eng. 2025;9(4):432\u2013438.","journal-title":"Nat Biomed Eng"},{"key":"e_1_3_3_527_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00795-x"},{"key":"e_1_3_3_528_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00900-0"},{"key":"e_1_3_3_529_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.005"},{"key":"e_1_3_3_530_2","unstructured":"National Cancer Institute. 2025. https:\/\/www.nih.gov\/about-nih\/nih-almanac\/national-cancer-institute-nci."},{"issue":"11","key":"e_1_3_3_531_2","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.1999.17.11.3540","article-title":"Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer","volume":"17","author":"Okamoto H","year":"1999","unstructured":"Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999;17(11):3540\u20133545.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_532_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jtcvs.2004.08.022","article-title":"Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come","volume":"129","author":"Brock MV","year":"2005","unstructured":"Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg. 2005;129(1):64\u201372.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"e_1_3_3_533_2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/JTO.0b013e318189a860","article-title":"The role of surgery in the treatment of limited disease small cell lung cancer: Time to reevaluate","volume":"3","author":"Lim E","year":"2008","unstructured":"Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: Time to reevaluate. J Thorac Oncol. 2008;3(11):1267\u20131271.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"e_1_3_3_534_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijrobp.2021.05.003","article-title":"Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: A multicenter, phase II, randomized trial","volume":"111","author":"Qiu B","year":"2021","unstructured":"Qiu B, Li Q, Liu J, Huang Y, Pang Q, Zhu Z, Yang X, Wang B, Chen L, Fang J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: A multicenter, phase II, randomized trial. Int J Radiat Oncol Biol Phys. 2021;111(2):424\u2013435.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"e_1_3_3_535_2","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.1995.13.10.2594","article-title":"Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study","volume":"13","author":"Loehrer PJ","year":"1995","unstructured":"Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study. J Clin Oncol. 1995;13(10):2594\u20132599.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_3_536_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/93.4.300","article-title":"Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study","volume":"93","author":"Pujol JL","year":"2001","unstructured":"Pujol JL, Daur\u00e8s JP, Rivi\u00e8re A, Quoix E, Westeel V, Quantin X, Breton JL, Lemari\u00e9 E, Poudenx M, Milleron B, et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst. 2001;93(4):300\u2013308.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"e_1_3_3_537_2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdj137","article-title":"A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer","volume":"17","author":"Schmittel A","year":"2006","unstructured":"Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, Reeb M, Thiel E, Keilholz U. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2006;17(4):663\u2013667.","journal-title":"Ann Oncol"},{"issue":"3","key":"e_1_3_3_538_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jnci\/87.3.183","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","volume":"87","author":"Arriagada R","year":"1995","unstructured":"Arriagada R, Le Chevalier T, Borie F, Rivi\u00e8re A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M, Benhamou S. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183\u2013190.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"e_1_3_3_539_2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","article-title":"Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597","volume":"21","author":"Masters GA","year":"2003","unstructured":"Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003;21(8):1550\u20131555.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_3_540_2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza MC","year":"2012","unstructured":"Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138\u20131145.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"e_1_3_3_541_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(16)30104-8","article-title":"Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): A multicentre, open-label, randomised phase 3 trial","volume":"17","author":"Goto K","year":"2016","unstructured":"Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(8):1147\u20131157.","journal-title":"Lancet Oncol"},{"key":"e_1_3_3_542_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2020.10.003","article-title":"Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment","volume":"150","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, L\u00f3pez-Vilari\u00f1o JA, Fern\u00e1ndez C, Kahatt C, Alfaro V, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020;150:90\u201396.","journal-title":"Lung Cancer"},{"key":"e_1_3_3_543_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.08.031"},{"issue":"2","key":"e_1_3_3_544_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan Y","year":"2021","unstructured":"Fan Y, Zhao J, Wang Q, Huang D, Li X, Chen J, Fang Y, Duan J, Zhou C, Hu Y, et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial. J Thorac Oncol. 2021;16(2):299\u2013309.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_545_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: A phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma S","year":"2024","unstructured":"Ma S, He Z, Liu Y, Wang L, Yang S, Wu Y, Chen H, Wu Y, Wang Q. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: A phase 2 investigator-initiated non-randomized controlled trial. EClinicalMedicine. 2024;70: Article 102543.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"e_1_3_3_546_2","doi-asserted-by":"crossref","first-page":"320S","DOI":"10.1378\/chest.106.6_Supplement.320S","article-title":"A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy","volume":"106","author":"Lad T","year":"1994","unstructured":"Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest. 1994;106(6 Suppl):320S\u2013323S.","journal-title":"Chest"},{"key":"e_1_3_3_547_2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1175960","article-title":"Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer","volume":"14","author":"Liu C","year":"2023","unstructured":"Liu C, Zeng L, Deng C, Jiang W, Wang Y, Zhou Y, Liu L, Wang S, Zhou C, Qiu Z, et al. Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer. Front Immunol. 2023;14: Article 1175960.","journal-title":"Front Immunol"},{"key":"e_1_3_3_548_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115660","article-title":"Intercalated Avelumab plus platinum-based chemotherapy in patients with extensive-stage small-cell lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study","volume":"228","author":"Linardou H","year":"2025","unstructured":"Linardou H, Papadopoulou K, Korfiatis N, Goussia A, Samantas E, Aravantinos G, Christopoulou A, Spathas N, Fountzilas E, Psyrri A, et al. Intercalated Avelumab plus platinum-based chemotherapy in patients with extensive-stage small-cell lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study. Eur J Cancer. 2025;228: Article 115660.","journal-title":"Eur J Cancer"},{"issue":"16","key":"e_1_3_3_549_2","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell HB","year":"2005","unstructured":"Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752\u20133759.","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_3_3_550_2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/JTO.0b013e318260de75","article-title":"Topotecan\/cisplatin compared with cisplatin\/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: Final results of a randomized phase III trial","volume":"7","author":"Fink TH","year":"2012","unstructured":"Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, et al. Topotecan\/cisplatin compared with cisplatin\/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: Final results of a randomized phase III trial. J Thorac Oncol. 2012;7(9):1432\u20131439.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"e_1_3_3_551_2","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.71.7454","article-title":"Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: A multicenter, adaptive, randomized phase III study (MATISSE)","volume":"35","author":"Jalal SI","year":"2017","unstructured":"Jalal SI, Lavin P, Lo G, Lebel F, Einhorn L. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-cell lung cancer: A multicenter, adaptive, randomized phase III study (MATISSE). J Clin Oncol. 2017;35(23):2619\u20132623.","journal-title":"J Clin Oncol"},{"issue":"31","key":"e_1_3_3_552_2","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck M","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W, Pietanza MC, Wu Y-L, Zielinski C, Thomas M, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740\u20133748.","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_3_3_553_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2007.14.3461","article-title":"Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103","volume":"26","author":"Rudin CM","year":"2008","unstructured":"Rudin CM, Salgia R, Wang X, Hodgson LD, Masters GA, Green M, Vokes EE. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008;26(6):870\u2013876.","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_3_3_554_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/JTO.0000000000000343","article-title":"A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer","volume":"10","author":"Lu S","year":"2015","unstructured":"Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10(1):206\u2013211.","journal-title":"J Thorac Oncol"},{"issue":"15","key":"e_1_3_3_555_2","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","article-title":"Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study\u2014CALGB 30504 (Alliance)","volume":"33","author":"Ready NE","year":"2015","unstructured":"Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study\u2014CALGB 30504 (Alliance). J Clin Oncol. 2015;33(15):1660\u20131665.","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_3_3_556_2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)","volume":"13","author":"Gadgeel SM","year":"2018","unstructured":"Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13(9):1393\u20131399.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_557_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2014Results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters S","year":"2022","unstructured":"Peters S, Pujol JL, Dafni U, D\u00f3mine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2014Results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial. Ann Oncol. 2022;33(1):67\u201379.","journal-title":"Ann Oncol"},{"issue":"8","key":"e_1_3_3_558_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0000000000000588","article-title":"Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy","volume":"10","author":"Evans TL","year":"2015","unstructured":"Evans TL, Cho BC, Udud K, Fischer JR, Shepherd FA, Martinez P, Ramlau R, Syrigos KN, Shen L, Chadjaa M, et al. Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy. J Thorac Oncol. 2015;10(8):1221\u20131228.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"e_1_3_3_559_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105918","article-title":"A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)","volume":"11","author":"Navarro A","year":"2026","unstructured":"Navarro A, Thomas A, Cheng Y, Chen Y, Reguart N, Yoshida T, Cousin S, Dong X, Yamamoto N, Cappuzzo F, et al. A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250). ESMO Open. 2026;11(1): Article 105918.","journal-title":"ESMO Open"},{"issue":"19","key":"e_1_3_3_560_2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel DR","year":"2024","unstructured":"Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC-H, Stojanovic G, Jove M, Rich P, Andric ZG, Wu Y-L, et al. RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer. J Clin Oncol. 2024;42(19):2317\u20132326.","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_3_3_561_2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/JTO.0b013e3181f77b6e","article-title":"Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: A safety, feasibility, and efficacy study from the Hoosier Oncology Group","volume":"5","author":"Jalal S","year":"2010","unstructured":"Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: A safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010;5(12):2008\u20132011.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"e_1_3_3_562_2","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.2013.51.4109","article-title":"Southwest oncology group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer","volume":"32","author":"Allen JW","year":"2014","unstructured":"Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Southwest oncology group S0802: A randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014;32(23):2463\u20132470.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_3_563_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial","volume":"14","author":"Pujol J-L","year":"2019","unstructured":"Pujol J-L, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. J Thorac Oncol. 2019;14(5):903\u2013913.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_3_564_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0013"},{"key":"e_1_3_3_565_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107932","article-title":"Phase I\/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study","volume":"195","author":"Malhotra J","year":"2024","unstructured":"Malhotra J, Chiappori A, Fujioka N, Hanna NH, Feldman LE, Patel M, Moore D, Chen C, Jabbour SK. Phase I\/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study. Lung Cancer. 2024;195: Article 107932.","journal-title":"Lung Cancer"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/cancomm.0052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:02:24Z","timestamp":1791273744000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/cancomm.0052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":564,"alternative-id":["10.34133\/cancomm.0052"],"URL":"https:\/\/doi.org\/10.34133\/cancomm.0052","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2026-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0052"}}